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Consensus guideline for the diagnosis and
treatment of tetrahydrobiopterin (BH4)
deficiencies
Thomas Opladen1*†, Eduardo López-Laso2†, Elisenda Cortès-Saladelafont3,4†, Toni S. Pearson5, H. Serap Sivri6,
Yilmaz Yildiz6, Birgit Assmann1, Manju A. Kurian7,8, Vincenzo Leuzzi9, Simon Heales10, Simon Pope10,
Francesco Porta11, Angeles García-Cazorla3, Tomáš Honzík12, Roser Pons13, Luc Regal14, Helly Goez15,
Rafael Artuch16, Georg F. Hoffmann1, Gabriella Horvath17, Beat Thöny18, Sabine Scholl-Bürgi19, Alberto Burlina20,
Marcel M. Verbeek21, Mario Mastrangelo9, Jennifer Friedman22, Tessa Wassenberg14, Kathrin Jeltsch1†,
Jan Kulhánek12*†, Oya Kuseyri Hübschmann1† and on behalf of the International Working Group on
Neurotransmitter related Disorders (iNTD)

Abstract
Background: Tetrahydrobiopterin (BH4) deficiencies comprise a group of six rare neurometabolic disorders
characterized by insufficient synthesis of the monoamine neurotransmitters dopamine and serotonin due to a
disturbance of BH4 biosynthesis or recycling. Hyperphenylalaninemia (HPA) is the first diagnostic hallmark for most BH4
deficiencies, apart from autosomal dominant guanosine triphosphate cyclohydrolase I deficiency and sepiapterin
reductase deficiency. Early supplementation of neurotransmitter precursors and where appropriate, treatment of HPA
results in significant improvement of motor and cognitive function. Management approaches differ across the world
and therefore these guidelines have been developed aiming to harmonize and optimize patient care. Representatives
of the International Working Group on Neurotransmitter related Disorders (iNTD) developed the guidelines according to
the SIGN (Scottish Intercollegiate Guidelines Network) methodology by evaluating all available evidence for the
diagnosis and treatment of BH4 deficiencies.
Conclusion: Although the total body of evidence in the literature was mainly rated as low or very low, these consensus
guidelines will help to harmonize clinical practice and to standardize and improve care for BH4 deficient patients.
(Continued on next page)
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Background
Introduction

Tetrahydrobiopterin (BH4) deficiencies comprise a group
of six rare neurometabolic disorders caused by pathogenic
variants in five genes responsible for the biosynthesis and
regeneration of BH4, which is the essential cofactor of the
aromatic amino acid hydroxylases phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH), two isoforms of
tryptophan hydroxylase (TPH 1/2), alkylglycerol monooxygenase (AGMO), as well as of three isoforms of nitric
oxide synthase (NOS 1–3) (Fig. 1). Since TH and TPH are
key enzymes in the synthesis of the monoamines dopamine, serotonin, norepinephrine, and epinephrine, a disturbance of BH4 metabolism results in a severe depletion
of all monoamine neurotransmitters. In addition, as PAH
mediates the conversion of phenylalanine (Phe) to tyrosine
(Tyr), hyperphenylalaninemia (HPA) is present in all BH4
deficiencies apart from autosomal dominant guanosine
triphosphate cyclohydrolase I deficiency (AD-GTPCHD)
and sepiapterin reductase deficiency (SRD) [1, 2]. ADGTPCHD is the most common cause of dopa-responsive
dystonia (DRD), a clinical syndrome characterized by dystonia that fluctuates diurnally and responds very well to
treatment with levodopa (L-Dopa). AD-GTPCHD is also
called autosomal dominant Segawa syndrome (DYT5a),
whereas autosomal recessive Segawa syndrome is usually
caused by autosomal recessive mutations of the TH gene
(DYT5b).
BH4 synthesis and regeneration is a multistage process
involving a series of steps catalysed by five enzymes.
Guanosine triphosphate cyclohydrolase I (GTPCH, EC
3.5.4.16), 6-pyruvoyltetrahydropterin synthase (6-PTPS,
EC 4.2.3.12), and sepiapterin reductase (SR, EC 4.1.1.17)
are the enzymes for BH4 biosynthesis. Pterin-4-alphacarbinolamine dehydratase (PCD, EC 4.2.1.96) and qdihydropteridine reductase (DHPR, EC 1.5.1.34) ensure
BH4 regeneration (Fig. 1). All the disorders are inherited
in an autosomal recessive (AR) manner, apart from
GTPCH deficiency (GTPCHD), which manifests with
both autosomal recessive and autosomal dominant (AD)
inheritance patterns (Table 1).
The precise global prevalence of BH4 deficiencies remains unknown and great variance can be found among
different countries [3, 4]. The mean incidence of all
HPAs detected by newborn screening (NBS) programmes in Europe is estimated to be approximately 1:
10000 [5], and BH4 deficiencies are presumed to

constitute around 1–2% of these cases. PTPS deficiency
(PTPSD) is the most frequent of all HPA -associated
BH4 deficiencies (approx. 54%), followed by DHPR deficiency (DHPRD, approx. 33%) [3]. For AD-GTPCHD a
prevalence of 2.96 per million was stated [6], however,
since many publications do not clearly classify the disease into DRD, AD or AR Segawa syndrome, and do not
always mention the underlying gene mutations, a final
assessment of the prevalence is not possible [7]. There
seems to be a high rate of undiagnosed patients [8-10].
Recently, a novel disorder to be included in the differential diagnosis of HPA has been identified: the disorder is
caused by biallelic mutations in the DNAJC12 gene and
is associated with a variable neurological phenotype in
association with HPA [11, 12].
Both laboratory and clinical findings in patients with
BH4 deficiencies are attributable to two main pathophysiologic mechanisms: HPA, and depletion of the
monoamine neurotransmitters in the central nervous
system (CNS).
Cerebral HPA toxicity is multifactorial. The most
prominent hypotheses discussed include: 1) competitive
inhibition of a blood-brain-barrier (BBB) transporter of
large neutral amino acids (LNAA) including tyrosine
and tryptophan with decreased protein and neurotransmitter synthesis; 2) decreased cholesterol synthesis and
myelin production, as well as direct myelin toxicity; 3)
tyrosine and tryptophan hydroxylase inhibition; 4) oxidative stress; 5) complex reduction of glutamatergic synaptic transmission; 6) pyruvate kinase inhibition; 7)
calcium homeostasis dysregulation [5, 13].
The second, and clinically dominant, pathophysiological
mechanism of neurological dysfunction in the BH4 deficiencies is shortage of the brain neurotransmitters dopamine, serotonin, and norepinephrine. Dopamine is most
commonly associated with the control of voluntary movement and reward-based learning and behaviour [14]. Norepinephrine is the modulator of arousal [15] and
serotonin affects predominantly higher cognitive functions
and behaviour. However, deeper insight into the complexity of CNS neurotransmission reveals that monoaminergic
neurons and their neurotransmitters share many common
properties, greatly overlap in numerous functions, and are
highly orchestrated to jointly modulate numerous brain
processes. As a result, dopamine, serotonin, and norepinephrine are all implicated in the modulation of higher cognitive and executive function, behaviour, mood, attention,
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Fig. 1 Biosynthesis and regeneration of tetrahydrobiopterin (BH4) and its functions as cofactor in the synthesis of serotonin, dopamine, and other
catecholamines as well as the catabolism of phenylalanine. Simplified scheme of the biosynthesis and regeneration of tetrahydrobiopterin (BH4)
in the presynaptic axonal end. BH4 serves as essential cofactor of the aromatic amino acid hydroxylases phenylalanine hydroxylase (PAH), tyrosine
hydroxylase (TH), and tryptophan hydroxylase (TPH) which catalyse key reactions in the synthesis of the monoamines dopamine, serotonin,
norepinephrine, and epinephrine. Note that AGMO and NOSs are not depicted in this overview. 5-HIAA, 5-hydroxyindoleacetic acid; 5-HIAL, 5hydroxyindoleacetaldehyde; 7,8-BH2, 7,8-dihydrobiopterin; BH4, tetrahydrobiopterin; DOPAC, 3,4-dihydroxyphenylacetic acid; DOPAL, 3,4dihydroxyphenylacetaldehyde; DTDS, dopamine transport deficiency syndrome; GTP, guanosine-5′-triphosphate; HVA, homovanillic acid; OxoPH41, oxo-2-hydroxy-tetrahydropterin; PLP, pyridoxal 5′-phosphate; PTP, 6-pyruvoyltetrahydropterin; qBH2, quinonoid dihydrobiopterin; VLA,
vanillyllactic acid; VMA, vanillylmandelic acid; VMAT 2, vesicular monoamine transporter

pain perception, motor control, and many other brain
processes [16]. Attribution of any given clinical symptom to the deficiency of a single neurotransmitter is
therefore likely to be an over-simplification. However,
the general signs of dopamine deficiency include predominantly parkinsonism, and dystonic movements, in
young infants also tremorous or choreatiform and

various other involuntary movements, while serotoninergic deficiency is thought to manifest as sleep pattern disturbance, mood dysregulation and temperature
instability [17].
Following the two main underlying pathophysiologic
pathways, treatment strategies primarily aim at the correction of peripheral HPA and brain neurotransmitter
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Table 1 Nomenclature of BH4 disorders
Disease name

Alternative disease
name

Disease
abbreviation

Gene
symbol

Mode of
inheritance

Affected
enzyme

Disease
OMIM#

Autosomal dominant GTP cyclohydrolase I deficiency

Segawa disease

AD-GTPCHD,
DYT5a

GCH1

AD

GTPCH I

128230

Dopa-responsive
dystonia
Autosomal recessive GTP cyclohydrolase I
deficiency

–

AR-GTPCHD, DYT/PARK-GCH1

GCH1

AR

GTPCH I

233910

6-pyruvoyl-tetrahydropterin synthase
deficiency

–

PTPSD, DYT/PARK-PTS

PTS

AR

PTPS

261640

Sepiapterin reductase deficiency

–

SRD, DYT/PARK-SPR

SPR

AR

SR

612716

Q-dihydropteridine reductase deficiency

–

DHRPD, DYT/PARK-QDPR

QDPR

AR

DHPR

261630

Pterin-4-alpha-carbinolamine dehydratase
deficiency

Primapterinuria

PCDD

PCBD1

AR

PCD

264070

Abbreviations in the table: AR Autosomal recessive, AD Autosomal dominant, DHPRD Dihydropteridine reductase deficiency, GCH1 GTP cyclohydrolase 1, GTPCHD
Guanosine triphosphate cyclohydrolase I deficiency, PCBD1 Pterin-4 alpha-carbinolamine dehydratase, PCDD Pterin-4-alpha-carbinolamine dehydratase deficiency,
PTPSD 6-pyruvoyl-tetrahydropterin synthase deficiency, PTS 6-Pyruvoyltetrahydropterin synthase, QDPR Quinoid dihydropteridine reductase, SR Sepiapterin
reductase, SRD Sepiapterin reductase deficiency

deficiencies. We developed this first consensus guideline
for the diagnosis and management of BH4 deficiencies in
the context of the International Working Group on
Neurotransmitter Related Disorders (iNTD, www.intd-online.org) and by using the Scottish Intercollegiate Guideline Network (SIGN) methodology. The recommendations
are based on a systematic review of the available literature
and on consensus meetings of the iNTD guideline working group. The guideline is intended for metabolic specialists, child and adult neurologists, paediatricians, intensive
care specialists, nurses, and paramedical specialists involved in the care of patients with BH4 deficiencies.

coordinators in Heidelberg, Germany in November 2017
and a face-to-face meeting for the whole guideline group
in Athens, Greece in September 2018 (at the meeting of
the Society for the Study of Inborn Errors of Metabolism
(SSIEM)).
In adherence to Scottish Intercollegiate Guidelines
Network (SIGN) methodology, two external academic
reviewers with expertise in neurometabolic and movement disorders (Nicola Longo, Salt Lake City, USA and
Keith Hyland, Atlanta, USA) and additional lay reviewers
(Pauline Schleicher, Melanie Kahlo and Ivana Badnjarevic) were asked to comment on the guideline draft before submission.

Methods

Developing topics and key questions

Composition of the guideline working group and timeline

During the start-up meeting, the list of key questions
was discussed and refined. Key questions comprised the
following topics: Clinical Presentation, Diagnosis (laboratory tests, imaging, electrophysiological investigations, etc.), Treatment, Management of Complications
and Long-Term Follow-Up, Social Issues, and Transition
(Additional file 1: Table S1). All topics were considered
by each of the 4 different BH4 disorder subgroups.

An executive committee (TO (chairman), OKH (secretary, subgroup coordinator), ELL, ECS, JK (subgroup coordinators) and KJ (project coordination)) was appointed
to oversee the guideline development process. Four different subgroups were generated, headed by one of the
subgroup coordinators (AR/AD GTPCHD (ELL), PTPSD
(JK), DHPRD (ECS) and PCDD/SRD (OKH)). The guideline working group consisted of 24 child neurologists
and/or metabolic specialists (TO, ELL, ECS, TP, SSB,
BA, MK, VL, WL, FP, AGC, TH, RP, LR, HG, GFH, GH,
SBB, AB, MM, JF, TW, JK, OKH), 5 biochemists (RA,
BT, SH, SP, MV), and 1 research project manager (KJ)
from several European countries, the USA and Canada.
All group members are part of the iNTD network and
experienced in the diagnosis and treatment of BH4 deficiencies. The project was supported by patient organizations (see below, section on “Patient advocacy groups”).
The start-up meeting took place in Barcelona, Spain in
February 2017, followed by one meeting of the subgroup

Systematic literature search

A systematic literature review on BH4 and related names
was performed in spring 2017 on Pubmed, Cochrane
database, and the Cinahl database, using the following
search terms: “Tetrahydrobiopterin deficiency”, “BH4 deficiency”, “atypical PKU”, “atypical phenylketonuria”,
“PTPS deficiency”, “(6-)pyruvoyl-tetrahydropterin synthase deficiency”, “SR deficiency”, “sepiapterin reductase
deficiency”, “segawa(s) disease”, “GTPCH (I) deficiency”,
“GTP cyclohydrolase (I) deficiency”,“Guanosine (-5-) triphosphate cyclohydrolase (I) deficiency”,” DHPR
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deficiency”, “dihydropteridine reductase deficiency”,
“pterin (-4a-) carbinolamine dehydratase deficiency”,
“PCD deficiency“. No language or data filters were used.
Single newly published manuscripts with clear clinical
relevance for the guideline development were included in
the literature database until the end of guideline development process. Reference lists from review articles and key
case series were screened for additional hits and members
of the guideline group were asked to suggest relevant book
chapters. The flow chart in the supplementary material illustrates the literature search (Additional file 2: Figure S2).
Grading of evidence and recommendations

The guideline was developed according to methodology of the SIGN [18]. For rating the quality of evidence and defining the strength of recommendations,
SIGN is committed to using the Grading of Recommendations, Assessment, Development and Evaluation
(GRADE) methodology. The level of evidence of individual studies was rated from 4 (lowest) to 1++ (highest). Specific outcomes (e.g. effect of a specific drug
on hypotonia) were described in relation to the quality of evidence (very low, low, moderate or high) for
the total body of evidence. Recommendations were
rated as strong (for or against), conditional (for or
against), or classified with a recommendation for further research (Table 2).
Furthermore, Good Practice Points (GPP) were formulated based on the clinical experience of the guideline development group. Relevant papers were
evaluated by at least two guideline working group
members. Before and during meetings, the guideline
group members were trained in standardized literature
evaluation using SIGN/GRADE methodologies. All recommendations were discussed for consensus during
guideline group meetings.
Disclaimer

The purpose of this guideline is to improve care for patients with BH4 deficiencies. It is not intended to replace
sensible, well-informed clinical care. Although the guideline is based on the best available evidence, the body of
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evidence for these disorders is comprised mainly of nonanalytical studies and case reports. In addition, some
recommendations reflect expert, often consensus opinion. Nevertheless, we believe that this guideline, which is
meant to provide a solid foundation to caregivers of BH4
deficient patients, will improve the care for these patients around the world.

Clinical presentation
The data on the clinical phenotype of BH4 deficiencies
(BH4Ds) was collected from a retrospective analysis of
published case reports. The level of precision and proficiency regarding the recognition and the use of medical
terminology to describe clinical symptoms varied substantially among individual publications, resulting in a
certain level of imprecision. After the establishment of
the first registry on BH4Ds with HPA which gathered
clinical, biochemical, and treatment data (Database of
Patients and Genotypes Causing HPA/Phenylketonuria
(PKU) incl. BH4-Responsive Phenotype, BIODEF; http://
www.biopku.org/home/biodef.asp), more precise information on case series could be obtained for ARGTPCHD, PTPSD, DHPRD and PCDD [3, 19]. Since
2015, the International Working Group on Neurotransmitter related Disorders (iNTD; http://www.iNTD-online.org) provides the first patient registry for all
neurotransmitter - related disorders with a standardized
longitudinal assessment of complex patient data [20].
General clinical pattern of BH4Ds and differential
diagnosis

The cardinal symptoms of BH4Ds reflect dopamine deficiency as well as the imbalance of other neurotransmitters including serotonin, norepinephrine or epinephrine
in the CNS (Table 3). While the overall clinical phenotype of BH4Ds may overlap with numerous other disorders, e.g. cerebral palsy [21], certain clinical features may
raise the clinical suspicion for a disorder of impaired
neurotransmission (e.g. early onset parkinsonism, oculogyric crises, diurnal fluctuation of symptoms, or an unexplained cerebral palsy-like picture). It is important to
note that patients may show a wide spectrum of clinical

Table 2 Forms of recommendations
Judgment

Recommendation

Undesirable consequences clearly outweigh desirable consequences

Strong recommendation against

Undesirable consequences probably outweigh desirable
consequences

Conditional recommendation against

Balance between desirable and undesirable consequences is closely
balanced or uncertain

Recommendation for research and possibly conditional recommendation
for use restricted to trials

Desirable consequences probably outweigh undesirable
consequences

Conditional recommendation for

Desirable consequences clearly outweigh undesirable consequences

Strong recommendation for
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Table 3 Symptoms and signs described in the different BH4 deficiencies
PTPSD

DHPRD

AR-GTPCHD

SRD

PCDD

AD-GTPCHD

125

77

55

53

19

570

Developmental delay

+++

+++

+++

+++

+

(+)

(Axial) Hypotonia

+++

++

+++

+++

+

(+)

Poor head control

+

+

+

+

Hypertonia

++

++

++

++

(+)

++

Number of reported cases
Nervous system

(+)

Epilepsy

++

+++

+

+

Cognitive impairment

++

+

(+)

++

(+)

Impaired speech development

+

(+)

(+)

+++

(+)

Dysarthria

(+)

(+)

+++

(+)

+

+++

+++

Dystonia

+

+

++

+++

+++

Oculogyric crises

(+)

+

(+)

+++

(+)

Dyskinesia/other involuntary movements

+

+

(+)

+/++

Parkinsonism/hypokinesia

+

(+)/+

+

+++

(+)

Movement disorders
Diurnal fluctuation of symptoms

Gait difficulties

+++

Tremor

(+)

(+)

Ataxia

(+)

(+)

Hyperreflexia

(+)/+

+

Irritability

(+)/+

+

+
(+)

+

+
(+)

Other

Microcephaly

++

++

(+)

(+)

(+)

(+)

++

++

Hypersalivation

(+)

+

++

+/++

Feeding/swallowing difficulties

+

+

(+)

++

Behavioural problems

(+)

(+)

(+)

Psychiatric problems

(+)

(+)

++

+

(+)

(+)

++

(+)

Autonomous nervous system
Temperature instability
Gastrointestinal system

(+)

Psychological problems

Sleep problems
Endocrine disturbances
Growth-hormone deficiency

(+)

Low birth weight

++

Central hypothyroidism

(+)

MODY3-like diabetes

+

Other
Microcephaly

++

Fatigability

(+)

Recurrent chest infections

+

Prematurity

+

Hypomagnesemia

+

(+)

(+)
(+)

(+)

+
+

Symptoms and signs reported in 570 Patients with AD-GTPCHD, 55 patients with AR-GTPCHD, 125 patients with PTPSD, 77 patients with DHPRD, 53
patients with SRD and 19 patients with PCDD
Very frequently +++ (≥50%), frequently ++ (≥25- < 50%), infrequently + (≥10- < 25%), occasionally (+) (< 10%)
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severity, ranging from asymptomatic individuals requiring no treatment to very severe disease courses.
Clinical patterns specific of PTPSD, DHPRD, AR-GTPCHD,
and SRD

The most common symptoms prior to treatment initiation were assessed in 125 PTPSD, 77 DHPRD, 55 ARGTPCHD and 53 SRD patients. Hypotonia, impaired
motor development and cognitive development, movement disorders (mainly dystonia), and parkinsonism/
hypokinetic rigid syndrome (consisting of bradykinesia,
extrapyramidal rigidity (“cogwheel rigidity”), rest tremor
and/or postural instability) are the hallmarks of BH4Ds
and should prompt clinicians to include BH4Ds in the
differential diagnosis.
Table 3 summarizes frequencies of the individual
symptoms: Approximately 50–75% of patients with any
of these disorders have hypotonia, often combined with
poor head control and peripheral hypertonia, mainly of
the extremities. Developmental delay of variable severity
is another common symptom, described in > 50% of patients. Specific impairment of cognitive and speech development was reported in around 50% of SRD and
PTPSD patients and in substantially lower proportions
(5–15%) in the remaining BH4Ds. However, it should be
noted that in most studies, standardized neuropsychological assessment is lacking, so that there is a risk of
over- or underestimating cognitive function.
Movement disorders, mainly dystonia, have been reported in almost 60% of patients with SRD, but less frequently in other BH4Ds (10–35%). Oculogyric crises
were reported in 60% of patients with SRD and only in
5–15% of patients with DHPRD, AR-GTPCHD and
PTPSD. It is important to note that the SRD cohort is
comprised of patients whose clinical features have been
very precisely characterized. Therefore, it should be kept
in mind that these symptoms, as well as those described
below, may be just as common or even more common
in the BH4Ds other than SRD, but underestimated in
published reports where patients’ clinical phenotypes
were less precisely characterized.
Dyskinesia or other types of involuntary movements
such as rest/postural tremor were not frequent and occurred predominantly in SRD patients. Ataxia is not
often reported in any of the BH4D patient groups.
Early-onset parkinsonism or hypokinetic rigid syndrome is associated with only a limited differential diagnosis in infancy and childhood, and should prompt
clinicians to include investigations for BH4Ds in the
diagnostic approach. Parkinsonism or hypokinetic rigid
syndrome was identified in around 60% of SRD, 25% of
PTPSD, and 10% of DHPRD and AR-GTPCHD patients.
Diurnal fluctuation of movement symptoms (worsening
over the course of the day; subsequent improvement
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after rest) is generally regarded as characteristic of
neurotransmitter disorders. It was, however, reported in
68% of patients with SRD and only around 10% of patients with AR-GTPCHD.
Patients with DHPRD in particular may develop epileptic seizures, while seizures are less common in patients with PTPSD, and occur rarely in SRD and ARGTPCHD. No specific type of epilepsy was identified.
Interestingly, roughly 10% of patients with PTPSD and
DHPRD were reported to have irritability and hyperreflexia, while these symptoms were reported in neither
SRD nor AR-GTPCHD.
Autonomic dysregulation, reflecting the disruption of
neurotransmitter homeostasis and most frequently manifesting as temperature instability, was documented primarily in SRD and AR-GTPCHD (almost 35%).
Excessive salivation was regularly reported in all BH4D,
again most commonly in AR-GTPCHD and SRD (25–
40%), and less frequently in DHPRD and PTPSD (5–
15%). Swallowing/feeding difficulties, presumably due to
overall motor impairment and/or oropharyngeal dystonia, were seen in 20 to 30% of patients with SRD,
PTPS and DHPRD.
Single case reports add endocrine dysfunction like
growth-hormone deficiency (PTPSD) or central
hypothyroidism (SRD) to the clinical phenotype [22, 23].
An increased frequency of prematurity has been reported in PTPSD and DHPRD. In PTPSD, a tendency
towards low birth weight has been observed [3]. Up to
25% of patients with DHPRD were reported to be microcephalic, as opposed to the other disorders, in which
microcephaly was reported in only 1% of patients.
Various psychiatric and behavioural problems (including depression, anxiety, psychosis, obsessive compulsive
features, impulsivity, and attention deficit disorder) as
well as sleep disturbance are reported infrequently in all
of the BH4Ds. However, psychiatric and behavioural
problems are likely underdiagnosed, except in SRD,
where they were documented in around 45% of patients
[21, 24–28].
R#1: (strong): In patients with unexplained alterations
in muscle tone (hypotonia/hypertonia), movement disorders (dystonia, oculogyric crises), parkinsonism or hypokinetic rigid syndrome, autonomic dysfunction or
diurnal fluctuation of symptoms, BH4Ds should be
considered.
R#2: (strong): Clinical follow-up should include the
assessment of psychiatric or behavioural problems and
sleep disorders.
Clinical patterns specific to PCDD

PCDD represents the rarest BH4D. A clear clinical description has been documented in the literature in only
19 patients (Table 3). In the BIODEF database most
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patients were reported to be asymptomatic (as of
01.05.2019), although a few patients exhibited transient
alterations in muscle tone, slight tremor or transient and
very mild delay in motor development [29]. However,
mutations in PCBD1 are associated with both hypomagnesaemia and risk for HNF1A-like Maturity Onset Diabetes of the Young (MODY3) diabetes in puberty [30],
so patients with PCBD1 mutations should be screened
for these disorders.
R#3: (strong): Patients with PCDD should be screened
for hypomagnesaemia and the development of HNF1Alike MODY3 diabetes during puberty.

Specific clinical pattern of AD-GTPCHD

Data regarding the clinical spectrum of AD-GTPCHD
prior to treatment initiation was reviewed in 570 patients (Table 3). Clinical symptoms in AD-GTPCHD
differ substantially in many aspects from the
remaining BH4Ds. The phenotype is milder and in
more than 50% of cases dominated by postural or
action-induced dystonia of one or both lower limbs
manifesting as gait difficulties. Diurnal fluctuation of
motor symptoms, with worsening later in the day, is
a very characteristic finding in AD-GTPCHD, especially during the first 3 decades [9]. Later, fluctuations
become less prominent. If not treated, focal or segmental dystonia typically progresses to multifocal or
even generalized dystonia (observed in 15%), together
with the development of parkinsonian signs in some
cases (reported in 13%). The clinical presentation in
the second decade of life is characterized by action
dystonia of the upper limbs, sometimes associated
with cervical impairment, asymmetric tremor and parkinsonism [8]. After the age of 20 years the predominant (> 80%) presentation is parkinsonism (isolated or
combined with dystonia). The progression of the dystonia (in both symptom severity and spread of symptoms to previously unaffected body parts) and the
diurnal fluctuation of symptoms subside with age and
the disease becomes almost stable in the fourth decade. Increased risk of typical degenerative parkinsonism has been reported in adulthood with rare GCH1
variants [31]. Psychiatric disorders have been reported
in 10% of patients. Other symptoms observed in the
recessive forms of BH4D, such as hypotonia, developmental delay, cognitive impairment, oculogyric crises
or epilepsy, occur extremely rarely in patients with
AD-GTPCHD.
R#4: (strong): In patients with dystonia, especially of
the lower limbs, with onset in the first or second decade
of life associated with diurnal fluctuation of symptoms
and normal development, possibly accompanied by parkinsonism, AD-GTPCHD should be considered.
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Age of onset and age of diagnosis

Precise data on the age of disease onset and the age of
diagnosis could not be reliably gathered from a retrospective analysis of published case reports. However, up
to 40% of patients with BH4Ds can be asymptomatic
during the neonatal period. With increasing age, the percentage of asymptomatic patients decreases significantly
(except PCDD) [3].
BH4Ds presenting with HPA can be detected by NBS
and are therefore diagnosed early (between 2 and 14
days of life) [3]. The absence of HPA in SRD markedly
delays the diagnosis (mean age at diagnosis 8.9 years), although the first symptoms may be apparent as early as
within the first 18 months of life [3, 21, 27, 32]. In ADGTPCHD patients, disease onset is typically during the
first decade of life (mainly between 3 to 9 years of age),
although very rarely patients may present with dystonia
and/or developmental delay in the first 12–18 months
[33, 34]. Disease onset in the second decade is also common. The average delay in diagnosis (in the time before
easily accessed diagnostic whole exome sequencing) has
been stated to be around 10 years [10].
Phenotype correlations with genotype or biochemical
phenotype

There are many different variants described in all BH4D
genes (Table 1). The detailed list is constantly updated
(see https://www.ncbi.nlm.nih.gov/clinvar/, http://www.
hgmd.cf.ac.uk or https://omim.org, search term “tetrahydrobiopterin” assessed December, 2019) and is beyond
the scope of this guideline project.
For PCDD, AR-GTPCHD, DHPRD, and PTPSD, there
are no consistent reports on genotype–phenotype correlation. For AD-GTPCHD, there is certain heterogeneity:
Some publications discuss and exclude genotypephenotype correlation [35, 36]. Others describe different
large heterozygous GCH1 deletions with high penetrance
and association with multifocal dystonia and adult onset
in a Taiwanese DRD population [37]. In 43 patients with
SRD with 16 different SPR mutations, no clear genotype–phenotype correlation was documented [21].

Diagnosis: laboratory tests
Key diagnostic test: newborn screening

The pattern of increased Phe concentrations with reduced Tyr concentrations resulting in elevated phenylalanine/tyrosine ratio detects all forms of HPA in
national newborn screening (NBS) programs [38].
Among the BH4 disorders, AR-GTPCHD, PTPSD,
DHPRD and PCDD classically present with HPA. Detailed results of NBS are available from 15 ARGTPCHD, 305 PTPSD, 46 DHPRD, and 18 PCDD cases.
Patients with AR-GTPCHD can be missed on NBS due
to missing HPA [19, 39, 40], while those published cases
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where HPA on NBS in DHPRD was not detected, are
more likely due to unreliable (historical) methods of Phe
detection (e.g. Phenistix [41, 42];). In comparison, NBS
was negative in two cases of PTPSD. However, retrospective re-evaluation revealed that the analysis was
most likely done by the semiquantitative bacterial inhibition assay (Guthrie method), known to cause falsenegative results [43, 44]. In PCDD, all reported cases
presented with HPA. The level of HPA in NBS can vary
widely and is not indicative of a specific BH4D. PCDD
tends to be associated with lower Phe levels. No correlation has been observed between the NBS Phe level and
the subsequent disease course.
Today, levels of Phe and Tyr are measured by tandem
mass-spectrometry (MS). The measurement of Phe in
dried blood spot (DBS) is a temperature and light stable
method, and available in many countries worldwide.
R#5 (strong): Newborn screening for PKU should be
performed in all countries following standardized protocols and using modern laboratory techniques to identify
elevated levels of Phe. Detection of HPA may be the first
clue for underlying AR-GTPCHD, PTPSD, DHPRD or
PCDD.
R#6 (strong): NBS is not a suitable diagnostic tool for
AD-GTPCH and SRD.
R#7 (GPP): Patients diagnosed with HPA on NBS
should be referred to a specialized metabolic centre for
further diagnostic evaluation and prompt initiation of
treatment.
Key diagnostic test: blood phenylalanine (plasma/serum)

As in DBS, increased Phe concentrations in plasma point to
all forms of HPA [38]. Although the measurement of Phe
concentrations in DBS with MS has several advantages over
plasma analysis (easier to obtain and transport, minimal
sample preparation, stable metabolites in DBS), there is evidence that Phe quantification in plasma is more precise
[45]. Comparison studies of simultaneous measurement of
Phe concentration using a MS or an ion-exchange chromatography protocol in either DBS or plasma samples indicated that Phe concentrations were up to 26% lower if
measured in DBS [46].
R#8 (conditional): Any newborn screening result of
HPA should be confirmed by quantification of the Phe
level in plasma before treatment is started.
Key diagnostic test: Pterins in DBS and urine

Apart from BH4Ds, the differential diagnosis of HPA includes phenylalanine hydroxylase (PAH) deficiency,
DNAJC12 deficiency, high natural protein intake, prematurity, and liver disease. One option to further investigate the underlying cause of HPA is the analysis of
pterins in DBS or urine. With the exception of ADGTPCHD and DHPRD, each BH4D presents with a
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specific pterin pattern [47] (Fig. 2). AR-GTPCHD reveals
low biopterin and neopterin (in DBS and urine). In
PTPSD, neopterin is highly elevated along with low
biopterin (DBS and urine). In PCDD, primapterin is high
in urine, while biopterin has been reported to be low to
normal, and neopterin normal to high. Primapterin is
not elevated in any other BH4D and cannot be reliably
detected in DBS. In DHPRD, no consistent pattern of
biopterin and/or neopterin levels DBS or urine has been
documented: Most patients showed normal neopterin
with low to normal biopterin, although a few had normal
to elevated neopterin with high biopterin. In some patients both elevated biopterin and neopterin were
observed.
In AD-GTPCHD, low to normal values of biopterin and
neopterin have been reported in urine [48]. There is no
data on DBS. Sepiapterin is typically elevated in SRD, but
can be detected in urine only via an additional assay [49].
Biopterin and neopterin are typically normal in DBS and
urine in this disorder.
In comparison to the analysis of DBS, the measurement
of pterins in urine is more sensitive due to their higher concentrations in urine. On the other hand, the DBS method
provides easy sample handling and low transport costs [50].
It should be noted that pterins in urine are more susceptible to degradation by light and high temperature than in
DBS. Collection and handling of both urine and DBS
should be performed by strictly following standardized procedures to ensure the accuracy of results. Both analyses are
available in specialized laboratories, mainly in first world
countries.
R#9 (strong): Strong recommendation for the analysis
of pterins in urine or DBS in patients with HPA on NBS.
Pterin analysis cannot rule out DHPRD (see below for enzyme activity measurements).
Be aware that analysis in urine is more sensitive than
in DBS, and that pathological patterns suggestive for
PCDD and SRD can only be detected in urine. In the
case of clinical suspicion, sepiapterin in urine must be
requested separately.
Note: Depending on availability and financial resources, a primary genetic HPA workup can be considered (see below).
R#10 (conditional/research): Analysis of pterins in
urine can be considered in patients with clinical suspicion
of AD-GTPCH, where cerebrospinal fluid (CSF) studies or
molecular genetic testing are not available.
Key diagnostic test: DHPR enzyme activity

DHPRD can be reliably detected only
ation of DHPR activity in DBS [51].
DHPR enzyme activity results in DBS
31 cases with AR-GTPCHD, in 1
GTPCHD, 176 cases with PTPSD,

by the determinIn the literature,
were reported in
case with AD151 cases with
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Fig. 2 Diagnostic flowchart for differential diagnosis of BH4Ds with and without HPA. 1Consider genetic HPA workup depending on availability
and financial resources. The gene panel should include the QDPR, GCH1, PTS PCBD1, SPR genes as well as DNAJC12. For GCH1, consider MLPA if
Sanger sequencing is negative. 2The analysis in urine is more sensitive than in DBS and pathological patterns suggestive for PCDD and SRD can
only be detected in urine but not in DBS. 3Primapterin measurement in urine is only elevated in PCDD. 4Aminoacids in CSF are not required for
diagnosis of BH4Ds. 5CSF analysis should always include standard measurements (cell count, proteins, glucose and lactate). 6Recommendation
against measurements of HVA, 5-HIAA, 5-MTHF, and pterins in CSF in the case of PCDD. (*) A diagnostic L-Dopa trial should be limited to children
with symptoms suggestive of dopa-responsive dystonia or to situations where biochemical and genetic diagnostic tools are not available. If the
diagnostic L-Dopa trial is positive but the results of CSF biochemical and/or molecular genetic testing are not compatible with AD-GTPCHD or
SRD, further aetiologies for dopa responsive dystonia should be considered (e.g. juvenile parkinsonism (PARK2gene)). (**) Can be considered if
available. See text for more detailed information. Abbreviations: 5-HIAA, 5-hydroxyindoleacetic acid; 5-MTHF, 5-methyltetrahydrofolate; AA: amino
acids; AD−/AR- GTPCHD: guanosine triphosphate cyclohydrolase I deficiency; BH4, tetrahydrobiopterin; Bio: biopterin; CSF: cerebrospinal fluid; DBS:
dry blood spot; DHPR: q-dihydropteridine reductase; DHPRD, dihydropteridine reductase deficiency; HVA, homovanillic acid; MRI, magnetic
resonance imaging; N: normal; NBS: newborn screening; Neo: neopterin; NR: not reported; PAH: phenylalanine hydroxylase; Phe: phenylalanine;
PKU: phenylketonuria; Prim: primapterin; PTPSD, 6-pyruvoyltetrahydropterin synthase deficiency; SRD: sepiapterin reductase deficiency; Tyr:
tyrosine; u: urine; (+) = positive effect; (−) = no or no clear effect

DHPRD, and 6 cases with PCDD. The analysis resulted
in a reduced DHPR activity only in DHPRD while being
normal in the other BH4Ds.
Although conclusions drawn from case reports and
small case series per se have low levels of evidence, the
findings were highly consistent in DHPRD. Of 151 reported patients, 150 had a reduced or even absent DHPR
activity in DBS in every laboratory. In one patient, normal DHPR activity was documented. However, the authors in that case consider technical problems to have
been highly likely, and reported that the parents did not
consent to a repetition of the analysis [52].
Measurement of DHPR activity in DBS is a light and
temperature sensitive method. It is available in specialized laboratories, mainly in first world countries.
R#11 (strong): Strong recommendation for the analysis of DHPR enzyme activity in DBS in patients with
HPA in NBS and/or in case of clinical suspicion of disorders of BH4 deficiency.
Key diagnostic test: lumbar puncture (HVA, 5-HIAA,
neopterin, biopterin and sepiapterin and 5-MTHF in CSF)

Secondary to the shortage of the essential cofactor BH4
and the consecutively impaired function of the aromatic
amino acid hydroxylases, levels of 5-hydroxyindoleacetic
acid (5-HIAA) and homovanillic acid (HVA) in CSF are
typically significantly low in the BH4Ds, apart from
PCDD [17]. Notably, normal levels of HVA and 5-HIAA
have been documented in published AD-GTPCHD cases
(normal HVA in 27% (5 of 18 patients) and normal 5HIAA in 45% (9 of 20 patients) and in approx. 37–41%
of PTPSD cases [25, 53–55], probably representing a
milder phenotype. In DHPRD, normal levels of HVA
were reported in 9/130 patients while normal 5-HIAA
levels were found in 2 patients [24, 56–58]. All patients
with SRD had low levels of HVA and 5-HIAA. However,
some patients were reported to have initially normal
CSF HVA and 5-HIAA levels associated with a mild

phenotype, before evolving to a more severe phenotype
associated with low CSF HVA and 5-HIAA levels.
Additional evaluation of CSF neopterin, total biopterin
or BH4, and dihydrobiopterin (BH2) makes it possible to
biochemically differentiate between the different BH4Ds
by determining the relevant level of the metabolic block
in BH4 biosynthesis or regeneration. Both neopterin and
biopterin are low in AR-GTPCHD and in most cases of
AD-GTPCHD, but in the latter an isolated neopterin decrease seems to be more frequent [59, 60]. High neopterin with low biopterin points to PTPSD. Depending on
the analytical method, elevated total biopterin or elevated BH2 points to DHPRD or SRD. Sepiapterin is
highly elevated in SRD and normal in all other BH4Ds.
Pterins in CSF are normal in PCDD.
5-methyltetrahydrofolate (5-MTHF) is one of the naturally occurring folates containing a methyl carbon unit attached to the N5 nitrogen atom [61]. The methyl unit in 5MTHF is essential for various processes in CNS including
the methylation of homocysteine to methionine, and the
formation of S-adenosyl-methionine (SAM). The latter is
required for more than 100 methylation reactions in cells,
including methylation of DNA, RNA, neurotransmitters,
lipids, hormones, and drug metabolites [61]. Due to the
close interplay between pterin and folate metabolism, depletion of 5-MTHF in the CSF can occur in BH4Ds. Hereby
specifically the DHPR enzyme supports dihydrofolate reductase (DHFR) to maintain folate in its active “tetrahydro”
form, in which it is capable of serving as a precursor for the
universal methyl donor substance SAM [62].
5-MTHF measurements in CSF were reported in 15 cases
with AR-GTPCH, 83 cases with PTPSD, 63 cases with
DHPRD and 3 cases with SRD. No reports were available
for AD-GTPCH and PCDD. In DHPRD, low levels of 5MTHF were reported [63] while patients with AR-GTPCH
and PTPSD have normal to low levels. 5-MTHF in SRD
was normal. In addition, high-dose L-Dopa/carbidopa supplementation can reduce CSF 5-MTHF levels [64].
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Analysis of dopamine and serotonin metabolites,
pterins, and 5-MTHF is performed in a limited number
of specialized laboratories. An online list of iNTD affiliated laboratories is available at the website www.intd-online.org. Collection and analysis of CSF metabolites
requires the use of strict protocols and timing to avoid
analytical pitfalls [65]. Since normal results of single parameters may be found, CSF analyses should always consist of a combination of monoamines (ideally including
3-O-methyldopa (3-OMD), l-3,4-dihydroxyphenylalanine
(L-Dopa), 5-hydroxytryptophan (5-HTP)), pterins, and
5-MTHF to ensure the correct interpretation of results
by pattern recognition. Patients’ medication at the time
of CSF sampling should be documented.
R#12 (strong): CSF analysis of HVA, 5-HIAA, pterins
and 5-MTHF is a reliable diagnostic method to differentiate between the BH4Ds. Specific measurements in CSF
should include the core metabolites HVA, 5-HIAA,
pterins and 5-MTHF. Pterins can be used to differentiate
between different BH4Ds.
R#13 (strong): Recommendation against measurement
of HVA, 5-HIAA, 5-MTHF, and pterins in CSF for
PCDD.
R#14 (GPP): CSF measurements should always include standard measurements (cell count, protein, glucose, lactate) considering possible differential diagnosis
e.g. infection or inflammation of different origin [65].
Collection and handling of CSF should be performed by
strictly following standardized procedures to ensure correct interpretation of results.
Key diagnostic test: genetic testing

For all enzymes involved in the biosynthesis or regeneration of BH4, gene variants have been reported in many
patients (see https://www.ncbi.nlm.nih.gov/clinvar/).
Therefore, mutation detection is the preferred method
for diagnosis confirmation or in case of non-conclusive
metabolite profiles. All BH4Ds are autosomal recessive
disorders apart from AD-GTPCHD where heterozygous
mutations in the GCH1 gene cause childhood-onset
dopa-responsive dystonia with diurnal fluctuation [66].
In GCH1, sequence alterations have been found by
Sanger sequencing in only 50 to 60% of clinically typical
AD-GTPCHD cases [67]. Since deletions can occur in
GCH1, the detection requires special methods such as
quantitative real-time polymerase chain reaction (qPCR)
or multiple ligation-dependent probe amplification
(MLPA) [35].
Recently, biallelic mutations in the DNAJC12 gene,
coding for a heat shock co-chaperone of the HSP40 family, have been identified in individuals with mild HPA
and a broad spectrum of clinical symptoms including
dystonia, speech delay, axial and limb hypertonia, parkinsonism and psychiatric features [12]. Treatment with
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sapropterin dihydrochloride and/or neurotransmitter
precursors L-Dopa/decarboxylase (DC) inhibitor and 5HTP had beneficial effects and resulted in the prevention of neurodevelopmental delay in individuals treated
before the onset of symptoms [11, 12]. Exclusion of
DNAJC12 gene variants has therefore been suggested to
be mandatory in all patients with HPA where pterins,
DHPR activity and PAH gene analysis are normal [11].
DNA (from peripheral blood cells, tissues, cultured
cells or dried blood spots) is the preferred sample.
The increasingly broad availability of multi-gene
panel testing or next-generation sequencing (NGS)
provides a time- and cost-effective approach that will
assist clinicians to identify the correct diagnosis in
patients with absent biomarkers or atypical clinical
features. The identification of disease-causing mutations facilitates accurate prenatal diagnosis, determination of the carrier status of family members, and
genetic counselling [68, 69].
R#15 (strong): Biochemical diagnosis of BH4Ds
should be confirmed by molecular genetic analysis.
R#16 (conditional): Depending on the availability and
the time to result, multi-gene panel testing or nextgeneration sequencing can be the first step to further
differentiate the underlying pathophysiology in patients
with HPA or to confirm BH4Ds in patients with a suspicious clinical presentation. The gene panel should include the QDPR, GCH1, PTS PCBD1, SPR, PAH and
DNAJC1 genes. If results of genetic testing are unremarkable, consider other known neurotransmitter disorders (e.g. tyrosine hydroxylase deficiency, aromatic lamino acid decarboxylase deficiency), especially in the
case of non-HPA.
Concluding statements regarding key diagnostic tests

R#17 (strong): There are 5 core diagnostic keys for
identifying BH4D (see Fig. 2 Diagnostic flowchart):
 Elevated Phe levels in NBS or selective diagnostic







work-up in patients with AR-GTPCHD, PTPSD,
DHPRD or PCDD.
Abnormal levels of biopterin, neopterin, primapterin
and/or sepiapterin in urine and DBS.
In DHPRD: decreased DHPR enzyme activity in
DBS.
Low CSF levels of 5-HIAA, HVA in combination
with altered levels of CSF pterins and/or high
sepiapterin in CSF.
Confirmation of pathogenic variants in the GCH1,
PTS, SRP, QDPR and PCBD1 genes.

Other diagnostic tests: blood prolactin

Dopamine acts as an inhibitor of prolactin secretion.
Therefore, prolactin in blood can be elevated in
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dopamine biosynthesis disorders [17]. Elevated prolactin
was found in 22 PTPSD [25, 70, 71], and 3 DHPRD cases
[72]. Prolactin was found normal in AD-GTPCHD subjects
[73]. In SRD, no reports on elevated prolactin levels were
available [21, 23, 74]. For AR-GTPCHD and PCDD, no literature evidence was available.
There are further notable reasons for increased prolactin levels in blood such as physiological or pathological
endocrine conditions, hypothalamus and pituitary disorders, systemic disorders, infections, drug related changes,
and post-ictal status [75, 76].
Measurement of prolactin in blood is an inexpensive
laboratory test that is available worldwide.
R#18 (research): Prolactin measurement can be part
of the diagnostic work-up for suspected dopamine deficiency, but it has low sensitivity and specificity. Recommendation for further research on prolactin levels at
diagnosis and during drug treatment.
Other diagnostic tests: serotonin (whole blood)

Whole blood serotonin was reported to be low in only 5
cases of SRD [21, 77]. In all other BH4Ds, no literature
evidence was available. Due to the very limited number
of patients, it is not possible to draw conclusions about
the diagnostic accuracy of this test.
R#19 (research): The role of serotonin measurement
in diagnosis and treatment monitoring should be evaluated in further research.
Other diagnostic tests: BH4 loading test

Determination of BH4-responsiveness in patients with
HPA can be done by oral BH4 loading test. The test was
initially also used to discriminate between patients with
elevated phenylalanine levels due to PAH deficiency and
patients with elevated Phe levels due to BH4D [78]. At
present, there is no uniform test procedure available and
test protocols vary considerably from short duration (8
h) to extended duration (48 to 78 h) with repeated BH4
administration [79, 80]. Comparably, BH4 doses used
vary from 2.5 mg to 20 mg/kg BW and higher.
A BH4 loading test was performed in 7 studies with >
15 AR-GTPCHD patients, 33 studies with 443 PTPSD
patients, in 22 studies with 161 DHPRD patients, and 7
studies with > 12 PCDD patients. All studies have a low
or very low level of evidence according to GRADE.
There is no literature evidence available for AD-GTPCH
and SRD. Regarding the effect of BH4 on Phe levels,
studies are conclusive, documenting a significant decrease in Phe concentration within the first 8–12 h following BH4 load in AR-GTPCHD, PTPSD and PCDD.
In contrast, patients with DHPRD show a less prominent
Phe reduction during the same time period [3, 81, 82].
Sample collection for the BH4 test is minimally invasive. The test, however, requires blood sampling over 8-
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12 h and placement of a nasogastric tube for patients
who refuse to take BH4 by mouth.
R#20 (Conditional): The oral BH4 loading test can be
considered in patients with HPA for the assessment of
BH4-responsiveness.
R#21 (GPP): Test procedures for measuring BH4 responsiveness can follow local recommendations for HPA
patients. The procedure usually consists of baseline assessment of Phe concentration in blood at times − 24 h,
− 12 h, and 0 h (=basal measurement). This is followed
by the oral administration of 20 mg/kg BW of sapropterin dihydrochloride once daily, taken with a regular
meal on two consecutive days. Phe concentration in
DBS should be tested every 8 h for 72 h after exposure.
Other diagnostic tests: Phe loading test

Oral Phe loading has been used additionally for the differential diagnosis of dystonia and BH4Ds [83–85]. During the test, hepatic phenylalanine hydroxylase is
stressed by an oral Phe intake. In the setting of partial
BH4 deficiency, conversion of Phe to Tyr is compromised, resulting in an elevated Phe/Tyr ratio for up to 6
h. In addition, the physiological stimulation of BH4 biosynthesis via GTPCH feedback regulatory protein
(GFRP) by Phe is absent, and biopterin concentrations
remain low after Phe loading [86].
The available literature on Phe loading tests in patients
with BH4Ds is composed of 38 studies with > 31 ARGTPCHD patients, 13 studies with > 100 AD-GTPCHD
patients, one study on one PTPSD patient, 4 studies with 4
DHPRD cases and 4 studies with > 50 SRD patients. While
all studies constitute a low or very low level of evidence,
the conclusions that can be drawn are consistent: Plasma
Phe concentrations are elevated and tyrosine remains unchanged resulting in an increased Phe/Tyr ratio. Further
discrimination from heterozygous PKU patients becomes
possible by adding the analysis of biopterin in plasma or
DBS. The use of specific paediatric cut-off values improves
test sensitivity and specificity [86]. However, test results do
not correlate with clinical disease severity [87].
Phe loading is a time-consuming procedure and requires blood sampling over 4-8 h. In uncooperative patients, gastric tube placement may be required. The Phe
loading test should not be performed concurrently with
administration of BH4 [88].
R#22 (Conditional): The oral phenylalanine loading
test can be considered when there is clinical suspicion
for AR−/AD-GTPCHD and SRD, when first line diagnostic tests (CSF biogenic amines and pterins or genetic
studies) are not available.
Other diagnostic tests: L-Dopa loading test

A temporary therapeutic L-Dopa trial has been historically commonly used in children or adults with
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unexplained early-onset dystonia. However, there is a
paucity of knowledge available about the sensitivity and
specificity of this method. The present need for this test
has in addition been questioned given the increasing
availability of advanced biochemical, radiological and
molecular genetic investigations [89].
R#23 (GPP): The diagnostic L-Dopa trial should be
limited to children with features suggestive of doparesponsive dystonia such as lower limb dystonia with diurnal variation and absent HPA. Trial outcome should
be monitored by careful clinical assessment including
thorough (video supported) documentation of motor
dysfunction, autonomic dysfunction, and psychiatric
symptoms.
Other diagnostic test: lumbar puncture (amino acids in CSF)

Only 8 studies with 25 patients (22 cases of ARGTPCHD, 1 case of DHPRD and 2 cases of SRD) report
results of amino acids analysis in CSF. No data is available for AD-GTPCHD, PTPSD, and PCDD. Phenylalanine was normal to high in AR-GTPCHD and high in
DHPRD [51]. PCDD and SRD had normal Phe [23, 51,
90, 91].
The measurement of amino acids in CSF is available
in many laboratories, mostly located in first world
countries.
R#24 (research): Amino acids in CSF are not required
for diagnosing BH4Ds. For a better understanding of the
pathophysiological role of elevated Phe levels in BH4Ds
under treatment, we recommend the measurement of
Phe in CSF for future research studies.
Other diagnostic test: lumbar puncture (other metabolites
in CSF)

Low nitrite/nitrate levels in CSF were reported in 12
cases of PTPSD, 9 cases of DHPRD, and in 1 case of SRD
[92]. Low 3-Methoxy-4-hydroxyphenylglycol (MHPG)
was found in 5 DHPRD [93, 94] and in 4 SRD [95–97]
cases. Low concentrations of 3-Methoxytyramine (3MT), 3,5-Dihydroxyphenylglycine (DHPG), and 3,4Dihydroxyphenylacetic acid (DOPAC) were observed in
1 DHPRD case [98]. Noradrenaline/epinephrine in CSF
was normal in 1 DHPRD [99] and 1 PCDD patient [100].
Dopamine in CSF was reported to be normal in 1 PCDD
case. 5-HTP in CSF was low in 2 SRD cases and normal
in 1 case, and L-Dopa was normal in 1 SRD case [95, 97].
No reports on these parameters were available for ADGTPCH and AR-GTPCH deficiency.
All of these analyses are available only in specialized
laboratories, mostly located in first world countries.
R#25 (research): Recommendation for research on
quantification of CSF biomarkers (including nitrite, nitrate, MHPG, 3-MT, DOPAC) when lumbar puncture is
performed for other clinical reasons.
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Key diagnostic test: enzyme activity measurements

A strong recommendation for the analysis of DHPR enzyme activity in DBS in patients with HPA in NBS and/
or in case of clinical suspicion of disorders of BH4 deficiency has been given above (R#11).
Enzyme activity essays are also available for the other
BH4D and their results are described for 26 ARGTPCHD, 23 AD-GTPCHD, 91 PTPSD, 53 SRD cases
as well as 7 cases with PCD deficiency. As material
source, skin fibroblasts, blood (erythrocytes, lymphocytes), liver tissue, and cerebral frontal lobe tissue were
chosen. In AR-GTPCHD, PTPSD and SRD, the enzyme
activities showed diagnostically relevant reduced concentrations [24, 41, 101–105]. The residual enzyme activity
does not correlate with the subsequent disease course. A
clear description of the methods and source of tissues
for cases of PCDD is not available.
R#26 (conditional): Conditional recommendation
against enzyme measurement in all other BH4 deficiencies for confirmation of the diagnosis since other less invasive and more sensitive diagnostic options are
available.

Diagnosis: brain imaging

Cranial magnetic resonance imaging (cMRI) or computer tomography (cCT) results were reported in more
than 100 patients with all variants of BH4Ds apart from
PCDD. All patients with AD-GTPCHD showed normal
results. The highest rate of abnormal brain imaging results was reported in patients with DHPRD (all 8 cMRI
abnormal, 22 out of 24 cCT abnormal). Neuroradiological findings included brain atrophy, basal ganglia calcifications, white matter changes, ventricular dilatation,
areas of hypodensity, and global demyelinating signs
[3, 94, 106–112]. In PTPSD, 13/26 cMRI and 3/5
cCT were normal. Documented neuroradiological
findings were widespread delayed myelination, periventricular hyperintensities, brain atrophy, and one case of
brain calcifications [3, 47, 113–115]. Very few brain imaging studies showed abnormal results in SRD (5/47
cMRI) and AR-GTPCHD (1/10 MRI) [21, 116]. For other
imaging modalities like dopamine transporter (DAT)scan, Fluorodeoxyglucose Positron-emission tomography
(FDG PET), and F-Dopa PET, published data is scarce.
The overall evaluation of all relevant brain imaging
changes did not reveal any specific pattern of cMRI abnormalities for BH4Ds. Therefore, brain imaging is not
required for the diagnosis of BH4Ds. However, cMRI is
typically performed in the work-up of a patient with
movement disorders and/or neurodevelopmental delay
in order to exclude other underlying diseases. Furthermore, following standards of good clinical care, neuroimaging is always indicated if there is an unexpected
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deviation in the clinical course of patient already diagnosed with a BH4D.
R#27 (conditional): Routine imaging of the brain is
not required to diagnose BH4Ds.
R#28 (GPP): In the work-up of patients with movement disorders and/or neurodevelopmental delay, or in
case of an unexpected deviation of the clinical course in
patients with BH4D, cranial MR imaging should be
performed.
Diagnosis: prenatal diagnosis

If a confirmed diagnosis exists in an index patient, prenatal testing in following pregnancies is possible. The
early diagnosis is decisive for prenatally initiated treatment like L-Dopa supplementation, which has been
shown to be beneficial in AR-GTPCHD patients [68].
Furthermore, the parents and physicians can prepare for
adequate peri- and postnatal management. The method
of choice is mutation analysis in chorionic villus samples
or in amniotic fluid cells [117]. Pterin analysis in amniotic fluid are also possible but not available as a routine
diagnostic procedure [118].
R#29 (strong): Molecular genetic analysis is the preferred prenatal testing method for all BH4Ds.

Treatment
First-line treatment

The long-term neurodevelopmental outcome of BH4D patients is strongly influenced by the early initiation of effective treatment [3], therefore therapy must not be delayed.
Based on evaluation of the literature, evidence exists for
(maintenance) drug therapy, including dosage and side effects, for Phe-reduced diet, sapropterin dihydrochloride, LDopa with peripheral DC inhibitor (carbidopa or benserazide), 5-HTP, folinic acid, dopamine agonists (DA), selective monoamine oxidase (MAO) inhibitors (MAO-I),
anticholinergic agents, catechol-O-methyl transferase
(COMT) inhibitors, selective serotonin reuptake inhibitors
(SSRIs), benzodiazepines, melatonin, and botulinum toxin
injections. For L-Dopa without DC inhibitor, psychiatric
therapy, baclofen, and surgery treatment there was insufficient literature available to inform any recommendations.
Note: For all treatment options, the total body of evidence in the literature was rated as low or very low.
Multiple studies referred to the same data basis within
the BIODEF database. Positive, neutral, and negative
(“side effects”) treatment effects are summarized in the
following sections. Detailed dose recommendations are
given in Table 4.
Dietary treatment

Phe-reduced diet The harmful effect of Phe accumulation in blood and brain is best witnessed in untreated
patients with PKU who develop irreversible neurological
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impairment and psychiatric symptoms if exposed to
HPA [5]. Although the precise pathogenesis of brain
dysfunction is still unclear, there is strong rationale for
reducing HPA and maintaining satisfactory low Phe
levels in all BH4Ds with HPA [120]. The two available
strategies to treat HPA are a Phe-reduced diet or
sapropterin dihydrochloride supplementation.
Phe-reduced diet was used in 5 AR-GTPCHD patients
in 5 studies, 103 PTPSD patients in 25 studies, 115
DHPRD patients in 40 studies, and 29 PCDD patients in
5 studies. Use of the Phe-reduced diet was not reported
in any patient with SRD or AD-GTPCHD.
There is no precise data available regarding the daily
Phe tolerance in patients with BH4D and no precise data
on the number of patients who, after being originally
treated solely with a Phe-reduced diet, later switched to
sapropterin dihydrochloride supplementation or a combined Phe-reduced diet plus sapropterin dihydrochloride
treatment.
Clear positive effect of Phe-reduced diet on lowering
Phe levels was documented in the vast majority of patients. However, as HPA is only one of the pathophysiological mechanisms in BH4Ds, Phe-reduced diet as
monotherapy in AR-GTPCHD, PTPSD, and DHPRD
failed to improve symptoms such as hypotonia, hypertonia, developmental delay, dystonia, other involuntary
movements, sleep and mood disturbances or epileptic
seizures. In contrast, there are 2 reports of PCDD patients with muscular hypo/−or hypertonia and motor developmental delay who showed improvement following
treatment with a Phe-reduced diet only [53].
In the reviewed BH4Ds literature, no negative effects
of Phe-reduced diet have been documented. However,
unnecessary dietary restrictions should be avoided, and
daily Phe intake and tolerance closely monitored to
optimize the maximal natural protein intake. Symptoms
of Phe deficiency may include anorexia, listlessness, alopecia, perineal rash, poor growth or even death [5].
Note: As Phe levels in PCDD have nearly always been
reported to be only mildly elevated, relaxation and discontinuation of Phe-reduced diet and/or sapropterin
dihydrochloride supplementation can be attempted after
the first year of life under careful monitoring of Phe
levels.
R#30 (strong): Phe control should be applied in
BH4Ds with HPA (AR-GTPCHD, PTPSD, DHPRD and
PCDD). Phe control may be achieved by Phe-reduced
diet or sapropterin dihydrochloride supplementation
(see below). Phe levels should be regularly monitored in
DBS or blood. Target ranges should be determined by
local recommendations for the dietary treatment of
PKU.
R#31 (strong): Phe-reduced diet should not be used
in BH4Ds without HPA (AD-GTPCHD and SRD).

Target dose

All BH4D apart 0.1 mg/kg BW/day
from PCDD

Divided in 2–3 Titrate to clinical
doses/day
Symptoms

0.5 mg/kg/d
(or 30 mg/d)

(3.3 mg/d base / 4
mg/d salt)

75 μg/kg BW/day

Increase
every 7 days by
0.1 mg/kg BW/d

Increase
every 7 days by
5 μg/kg BW/d

Consider analysis of
CSF 5MTHF for dose
finding

5-HTP should follow L-Dopa/DCI
treatment initiation
Always in combination with a
peripheral decarboxylase inhibitor
(for example by simultaneous
application with L-Dopa/DC
inhibitor)

(2020) 15:126

Bromocriptinea
(Dopamine agonist)

Pramipexolea (Dopamine All BH4D apart 3.5–7 μg/kg/BW/day (base) Divided in 3
agonist)
from PCDD
5–10 μg/kgBW/day (salt)
equal doses/
Note: Distinction in salt
day
and base content!
(see product insert)

Titrate to clinical
Symptoms

No titration needed

Divided in 1–2 10–20 mg/day
doses/day

In DHPRD and
all BH4D with
low 5-MTHF
in CSF

Folinic acid

Second line treatment

Titrate slowly (1–2
mg/kg BW/day
per week)
depending on clinical
picture and side
effects
Consider analysis of
CSF 5HIAA for dose
finding

Divided in 3–6 Published target dose
doses/day
recommendations are
highly variable
5-HTP doses are
usually lower than
L-Dopa doses

All BH4D apart 1–2 mg/kg BW/day
from ADGTPCHD and
PCDD

5-Hydroxytryptophan
(5-HTP)

Increase 0.5–1 mg/kg In young infants at least as many
BW/day per week
dosages as meals would be ideal
Follow BW adaption
(usually 5–6 /day)
until the BW of 40 kg.
After 40 kg adjust
depending on clinical
symptoms
Consider analysis of
CSF HVA for dose
adjustment

Divided in 2–6 AD-GTPCHD:
doses/ day
3–7 mg/kg
BW/day
All other BH4D:
10 mg/kg BW/day
or maximally
tolerated dosage
Dose recommendation
relates to L-Dopa
component!

All BH4D apart 0.5 mg–1 mg/kg BW/day
from PCDD
Dose recommendation
relates to L-Dopa
component!

L-Dopa/DC inhibitor
(carbidopa/
benserazide) 4:1
Depending on
clinical symptoms.
Some patients need
more than 10 mg/kg
BW/day for resolving
clinical symptoms

Titrate dose according Follow PKU national treatment
to Phe levels in DBS
recommendations
or plasma
Use either Phe reduced diet or
Sapropterin dihydrochloride to
control Phe levels

Follow PKU national treatment
recommendations
Use either Phe reduced diet or
Sapropterin dihydrochloride to
control Phe levels

Comment

All BH4D with
HPA apart
from DHPRD

Management
suggestion

Sapropterin
dihydrochloride

20 mg/kg BW/day

Maximum dose

Titrate Phe restriction
according to Phe l
evels in DBS or
plasma
Divided in 1–3 5–10 mg/kg
doses/ day
BW/day

Doses

All BH4D with
HPA

2-5 mg/kg BW/day

Starting dose

Phe-reduced diet

First line treatment

Disorder

Table 4 Recommended drugs and doses for BH4 disorders
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All BH4D apart 0.1 mg/kg BW/day
from PCDD
ATTENTION: orally
disintegrating preparation
needs much less dosage
because of missing firstpass effect in the liver

Selegilinea
(MAO B inhibitor)

All BH4D apart 200 mg
from PCDD
(adult)

All BH4D apart 6–12 years: 25 mg/day
from PCDD
in 1 dose
> 12 years: 50 mg/day
in 1 dose

All BH4D apart 0.01–0.03 mg/kg/day
from PCDD

Entacaponea
(COMT inhibitor)

Sertalinea
(SSRI)

Melatonina

6–12 years:
in 1 dose
> 12 years:
in 1 dose

< 15 kg: in 1
dose
> 15 kg:
in 2 doses

Divided in 2
(−3) doses/
day

Doses

Children 50 mg/day

Effective dose
highly variable
(6–60 mg)
Titrate to clinical
Symptoms

Titrate to clinical
Symptoms

Titrate to clinical
Symptoms

Target dose

5–8 mg/day

50 mg/day
< 12 years
200 mg/day
> 12 years

Up to 2.000 mg

Maximum dose:
< 15 kg BW
30 mg/day
> 15 kg BW
60 mg/d

0.3 mg/kg/d
(or 10 mg/d)

8 mg/day

Maximum dose

6–12 years: increase
after 7 days to 50
mg/day
in 1 dose
> 12 years 50
mg/day in 1 dose

by 1–2 mg/d in
2–4 doses/d

Increase every 7 days

Increase every 2
weeks by 0.1
mg/kg BW/d

Increase weekly
by 1 mg

Management
suggestion

Slow release preparation for sleepmaintenance insomnia available in
some countries

Don’t stop treatment suddenly
Note: Elevated risk of serotonin
syndrome
(SS) or malignant neuroleptic
syndrome (MNS) when used with
drugs impacting serotonergic
pathway (e.g. 5-HTP, MAO inhibitors)

In many countries licensed only
for adults.
Comedication with L-Dopa/DC
inhibitor
Consider reduction of concomitant
L-Dopa supplementation (10–30%)

Consider side effects: like dry
mouth, dry eyes, blurred
vision (mydriasis), urine
retention, constipation.

Can cause sleep disturbances –
morning and afternoon or
lunchtime dosage is possible
ATTENTION: orally disintegrating
preparation needs much less
dosage because the first-pass
effect of the liver is avoided

Children > 12 years
Exchange patch every 24 h

Comment

Please note: The doses given are in a range typically used and have been published. In individual patients, some adjustment may be necessary depending on symptom response and side effects
a
The evaluated literature did not provide BH4D specific treatment dose recommendations for this drug. The listed doses, therefore, indicate treatment recommendations from Summary of Product Characteristics
(SmPC) or neurotransmitter related publications (e.g. [119])
Abbreviations: 5-HIAA 5-hydroxyindoleacetic acid, 5-HTP 5-hydroxytryptophan, 5-MTHF 5- methyltetrahydrofolate, HVA Homovanillic acid, AD-GTPCHD Autosomal-dominant GTPCHD: guanosine triphosphate
cyclohydrolase I deficiency, BH4D Tetrahydrobiopterin deficiency, BW Body weight, COMT Catechol-O-methyl transferase, CSF Cerebrospinal fluid, DBS Dry blood spot, DC Decarboxylase, DCI Decarboxylase inhibitor,
DHPRD Dihydropterin reductase deficiency, L-Dopa L-3,4-dihydroxyphenylalanine, MAO B Monoamine oxidase B, PCDD Pterin-4-alpha-carbinolamine dehydratase deficiency, Phe Phenylalanine, PKU Phenylketonuria,
SSRI Selective serotonin reuptake inhibitor

All BH4D apart < 15 kg: start 0.5–1 mg/
from PCDD
day
> 15 kg: start 2 mg/day

Trihexyphenidyla
(Anticholinergic drugs)

Third line treatment

All BH4D apart 2 mg/day
from PCDD

Starting dose

Rotigotinea (transdermal
dopamine agonist)

Disorder

Table 4 Recommended drugs and doses for BH4 disorders (Continued)
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R#32 (strong): Phe-reduced diet should not be used
in monotherapy for the treatment of neurological symptoms in BH4Ds.
Drug treatment

Sapropterin dihydrochloride The rationale for supplementation of sapropterin dihydrochloride, a synthetic
tetrahydrobiopterin analogue, is based upon the defective biosynthesis or recycling of this essential cofactor for
the aromatic L-amino acid hydroxylases in all types of
BH4Ds. The main effect of sapropterin dihydrochloride
supplementation lies within its marked impact on the
control of peripheral Phe levels. Animal studies have
demonstrated rather poor penetration of peripherally administered sapropterin dihydrochloride across the
blood-brain barrier and an increase of total biopterin
only after supplementation with doses not applicable in
clinical practice [121, 122]. Data concerning BH4 uptake
into the human brain, and correction of dopamine and
serotonin metabolism following sapropterin dihydrochloride administration, are very limited too [122].
Although sapropterin dihydrochloride is more expensive
than a Phe-reduced diet and is still unavailable in some
(European) countries, it enables a markedly higher natural protein intake and offers a much more convenient
way to treat HPA. Pharmacokinetic studies indicate a
mean elimination time of around 4–7 h depending on
the population studied. It can be administered in one
daily quantity and the target Phe concentrations should
follow the national recommendation for the treatment of
PKU.
The literature search identified approximately 40 ARGTPCHD patients from 16 studies, 397 PTPSD patients
from 41 studies, 194 DHPRD patients from 19 studies
(see note below), 29 PCDD patients from 10 studies, and
10 SRD patients from 9 studies treated with sapropterin
dihydrochloride, while no AD-GTPCHD patient on
sapropterin dihydrochloride was identified.
Evaluation of specific treatment effects of sapropterin
dihydrochloride was hampered by the use of cotreatment (L-DOPA/DC inhibitor, 5-HTP) in almost all
patients, except in PCDD. The assessment of the effects
of sapropterin dihydrochloride may therefore be biased.
Similar to a Phe-reduced diet, if co-administered with
neurotransmitter precursors, a sapropterin dihydrochloride treatment consistently improved almost all clinical
symptoms in PTPSD, DHPRD (see comment below),
and AR-GTPCHD, including movement disorders (dystonia, oculogyric crises, choreoathetosis, tremor, hypotonia, hypertonia, rigidity), epileptic seizures, sleep
problems, gastrointestinal disturbances (hypersalivation,
swallowing difficulties), anthropometric parameters, developmental delay, and behavioural abnormalities. In
addition, biochemical markers such as the concentration
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of CSF neurotransmitter metabolites were positively influenced. In SRD patients, however, no clear clinical
benefit was reported [21, 96].
Experience of sapropterin dihydrochloride monotherapy is mainly limited to mild forms of PTPSD with minimal or even absent clinical symptoms, and normal
levels of dopamine and serotonin metabolites in CSF
[44]. However, such patients need to be closely monitored as evolution from a mild into a severe phenotype
can occur, requiring the full treatment regimen with
dopamine and serotonin precursors [123]. A handful of
patients experienced improvement in developmental impairment, hypotonia, swallowing difficulties, hypersalivation, drowsiness or epileptic seizures when on
sapropterin dihydrochloride monotherapy.
If used as monotherapy, sapropterin dihydrochloride
has been reported in several cases to fail to improve or
prevent intellectual disability, movement disorders, seizures or sleep problems, and it also did not affect the
levels of CSF neurotransmitter metabolites [22, 25, 44].
No negative effects related to sapropterin dihydrochloride administration have been reported in the literature reviewed. According to the official drug
information, patients may commonly (≥1/10) or very
commonly (≥1/100 to < 1/10) experience headaches, rhinorrhoea, pharyngolaryngeal pain, nasal congestion,
cough, diarrhoea, abdominal pain, dyspepsia or nausea.
Note: Based on the hypothesis that sapropterin dihydrochloride supplementation may lead to increased 7,8dihydrobiopterin (BH2) production and a decreased
BH4/BH2 ratio resulting in aggravation of disease severity by inhibiting the aromatic L-amino acid hydroxylases
or by increasing nitric oxide (NO) uncoupling and oxidative stress, this treatment approach is currently controversial in DHPRD [124, 125]. However, literature
evidence for these potential harmful effects is scarce and
based on cell experiments only [124]. In contrast, there
are 194 patients with DHPRD (15 studies) received BH4
supplementation published who did not show any clinical or biochemical adverse effect that could be directly
related to BH4 supplementation. Furthermore, there is a
suggestion that restoration of the BH4 pool with BH4
supplementation may have a protective effect [125].
Therefore, there is no reliable justification to withhold
this therapeutic intervention from patients with DHPRD.
R#33 (strong): Phe control should be applied in
BH4Ds with HPA (AR-GTPCHD, PTPSD, DHPRD and
PCDD). Phe control is possible through a Phe-reduced
diet (see above) or through administration of sapropterin
dihydrochloride. Sapropterin dihydrochloride is the
treatment of choice in AR-GTPCHD, PTPSD, and
PCDD. It should be administered once daily and doses
should be titrated according to Phe levels. Phe levels
should be controlled in DBS or blood, and target ranges
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should follow local recommendations for the dietary
treatment of PKU. In PCDD, discontinuation of sapropterin dihydrochloride supplementation can be attempted
after the first year of life under careful Phe level
monitoring.
R#34 (conditional): In DHPRD, Phe-reduced diet and
not the supplementation of sapropterin hydrochloride is
nowadays considered the method of choice for the control of HPA. Since the available evidence against the use
of sapropterin dihydrochloride is scarce, sapropterin
dihydrochloride can be considered in DHPRD patients.
Phe levels should be controlled in DBS or blood, and
target ranges should follow local recommendations for
the dietary treatment of phenylketonuria.
R#35 (research): To better understand the pathophysiological mechanism and metabolic consequences of
sapropterin dihydrochloride treatment in DHPRD and
also the effect of sapropterin dihydrochloride monotherapy, we recommend further research on these topics.
L-Dopa with or without carbidopa/benserazide
BH4Ds result in significantly reduced dopamine availability in the CNS. L-Dopa, a dopamine precursor that is
converted to dopamine by the aromatic L-amino acid
decarboxylase (AADC) enzyme, has been widely used for
numerous indications in order to restore dopamine
homoeostasis. The addition of carbidopa or benserazide,
a peripheral DC inhibitor, blocks the peripheral decarboxylation of L-Dopa. This results in increased L-Dopa
concentrations at the blood-brain barrier and also in reduced peripheral L-Dopa side effects.
The effect of L-Dopa/carbidopa was described in 197
AD-GTPCHD patients in 32 studies, in 45 ARGTPCHD patients in 18 studies, in 540 PTPSD cases in
36 studies, in 249 DHPRD patients in 45 studies, in 49
SRD patients in 25 studies, and in one 1 PCDD patient.
The effect of L-Dopa/benserazide was documented in
11 AD-GTPCHD patients in 6 studies, in 11 PTPSD patients in 2 studies and in 4 SRD patients in 4 studies.
For L-Dopa/benserazide treatment in AR-GTPCHD,
DHPRD, and PCDD, no literature evidence is available.
It is not possible to judge the effect of L-Dopa without
a DC inhibitor since for 162 AD-GTPCHD patients in
32 studies, 1 AR-GTPCHD patient in 1 study, 47 PTPSD
patients in 4 studies, 21 DHPRD patients in 7 studies,
and 1 SRD patient, it was not clearly stated whether LDopa was used alone or in combination with a DC inhibitor. For PCDD, no literature evidence is available on
the use of L-Dopa without a DC inhibitor.
Note: Almost invariably, L-Dopa/DC inhibitor treatment
was
initiated
simultaneously
with
5hydroxytryptophan treatment (apart from ADGTPCHD). Evaluating the impact of these drugs separately may therefore be problematic and biased.
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Furthermore, the patients were concurrently treated with
sapropterin hydrochloride and on a Phe-reduced diet.
L-Dopa/DC inhibitor treatment in BH4D patients was
found to improve most disease-related symptoms in the
majority of studies. Positive treatment response correlated inversely with the age at treatment initiation [3,
82], however, treatment non-responders were reported
too.
The positive effects of L-Dopa/DC inhibitor treatment
in BH4Ds were observed on almost all clinical endpoints.
Improvements in motor development, cognitive functions, muscle tone abnormalities (hypotonia, poor head
control, hypertonia) and epileptic seizures were reported
in the largest proportion of patients. A positive effect
could also be observed on dystonia, including oculogyric
crises, dyskinesias and other movement disorders, parkinsonism, epileptic seizures, autonomic dysregulation
(temperature instability), gastrointestinal disturbances
(hypersalivation, swallowing difficulties), anthropometric
parameters (failure to thrive, growth retardation, microcephaly), sleep problems, behavioural and psychiatric
disorders or delayed speech development. Additionally, a
positive effect of L-Dopa/DC inhibitor treatment was reported on the level of various biochemical markers, including urinary pterins, CSF neurotransmitter
metabolites and prolactin.
In some patients, however, regardless of the BH4D
type, even combined treatment with L-Dopa/DC inhibitor failed to improve either disease symptoms or
biomarker results.
Negative effects reported in BH4D patients receiving
L-Dopa/DC inhibitor treatment correspond to the adverse effects generally observed with L-Dopa treatment.
The negative motor effects manifested mainly as dyskinesia and as motor fluctuations with on/off phenomenon.
Other movement disorders (tremor, chorea, myoclonic
jerks) were observed less frequently. Non-motor side effects of L-Dopa/DC inhibitor described included behavioural and psychiatric symptoms (anxiety, delusions,
impulsivity, irritability, hyperactivity, mood fluctuations
or panic attacks), sleep disturbances, gastrointestinal
problems (nausea, vomiting, diarrhoea) and headaches.
The most commonly used ratio of L-Dopa to DC inhibitor is 4:1. The available literature doesn’t allow an
evaluation of whether the 4:1 preparation has a superior
effect compared to the 10:1 preparation. According to
published drug information, there is no known upper
dose limit for DC inhibitor or any specific side effects
described. In contrast, side effects of L-Dopa in the context of DC inhibitor underdosing clearly justify sufficient
dosing.
From a pharmaceutical perspective, it is important
to mention that benserazide is unstable in the air.
During compounding, the substance oxidizes and can
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therefore become ineffective. Carbidopa, on the other
hand, is relatively stable. It can also be readily compounded into a formulation suitable for children.
Theoretically, drug forms for the preparation of suspensions are available. However, since there is no
uniform distribution in the suspension due to the undissolved particles, it is not recommended to divide a
suspension. If a suspension is used, it should be administered immediately after production.
R#36 (strong): L-Dopa should always be given in
combination with a DC inhibitor (4:1 ratio) and
should be the first line of treatment in AD-GTPCHD,
AR-GTPCHD, DHPRD, PTPSD, and SRD.
R#37 (strong): The L-Dopa/DC inhibitor starting
dose should be low, distributed in several daily dosages and slowly titrated depending on the clinical
symptoms. In case of side effects, the timing and dosing of medication may be adjusted individually. Referring to the normal range of dopamine metabolite
values in CSF, which is highest during the neonatal
and infantile period, the target treatment dose in all
infants (below 40 kg body weight) with BH4D (apart
from AD-GTPCHD) is 10 mg/kg BW/d (if clinically
tolerated). Some patients require higher doses. In ADGTPCHD, most patients obtain complete symptom
control with lower doses of L-Dopa /DC inhibitor.

5-Hydroxytryptophan Reduced bioavailability of serotonin in the CNS in BH4Ds results from impaired
conversion of tryptophan to 5-HTP by tryptophan hydroxylase 2 (TPH2), for which BH4 is an essential cofactor. The subsequent conversion of 5-HTP to
serotonin is carried out by the AADC enzyme, which
is unaffected in BH4Ds. This forms the pathophysiological rationale for the supplementation of 5-HTP in
BH4Ds with a potential to correct the neurotransmitter imbalance.
5-HTP was used in 41 AR-GTPCHD cases in 12 studies, in 4 patients with AD-GTPCHD in 1 study, in 542
PTPSD patients in 41 studies, in 93 DHPRD in 49 studies, 14 SRD patients in 19 studies, and in 1 PCDD
patient.
For all patients, except for one patient with PCDD,
overall clinical improvement on various endpoints was
reported.
Note: 5-HTP was used in combination with other
medications in all patients. 5-HTP treatment is often initiated simultaneously with L-Dopa/DC inhibitor and/or
sapropterin dihydrochloride /Phe-reduced diet, which
markedly hampers the assessment of the effects of 5HTP alone. 5-HTP treatment was started without LDopa/DC inhibitor in only in a handful of patients; the
reported effects are inconsistent among the studies.
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The observed positive effects of 5-HTP (at least in
co-administration with L-Dopa/DC inhibitor) include
improvement in almost all clinical endpoints including acquisition of developmental milestones, cognition, tone and movement disorders, epileptic seizures,
swallowing difficulties and hypersalivation, speech development, attention and behaviour, and mood (depression). Sleep disturbances have been reported to
improve with 5-HTP treatment. Due to comedication, the improvement could, however, only be
clearly assigned to 5-HTP supplementation in very
few patients. Psychiatric and behavioural problems,
other symptoms often associated with serotonin deficiency, were reported to improve in some patients as
well: In 4 AD-GTPCHD patients, depression improved
on 5-HTP in monotherapy or 5-HTP in combination
with serotonin agonists or serotonin reuptake inhibitors [126]. Interestingly, during a 5-HTP shortage
lasting for 6 months, no obvious neurologic deterioration could be observed in a cohort of 12 PTPSD patients [127].
As with L-Dopa/DC inhibitor treatment, 5-HTP administration failed to improve symptoms in some
patients.
The most common adverse effects of 5-HTP are
gastrointestinal problems (nausea, vomiting, diarrhoea,
abdominal pain). Indeed, these symptoms necessitated
5-HTP discontinuation in some cases. Irritability, choreoathetoid, dyskinetic or myoclonic movement disorders, and sweating were observed, too. Given its coadministration with L-Dopa/DC inhibitor, numerous
other adverse effects were observed, but from a pathophysiologic standpoint, these are more likely to be related entirely or at least partially to L-Dopa rather than
to 5-HTP treatment.
R#38 (strong): From a biochemical standpoint, 5-HTP
is considered a first line treatment in BH4Ds. In patients
with DHPRD, PTPSD, and SRD, benefits clearly outweigh adverse effects, leading to a strong recommendation for the use of 5-HTP in these disorders. For PCDD
and AD-GTPCHD, no recommendation can be given
due to lack of evidence.
R#39 (conditional): For AR-GTPCHD, desirable consequences probably outweigh undesirable consequences,
thus forming a conditional recommendation for the use
of 5-HTP in this disorder.
R#40 (strong): 5-HTP should follow initiation of the
L-Dopa/DC inhibitor treatment. There is no clear evidence for a starting dose; however, it should be lower
than the L-Dopa dose (e.g. Table 4). It should not be
changed at the same time as L-Dopa to clearly distinguish clinical effects. Start with a low dose and titrate
slowly as dictated by clinical symptoms. Use a peripheral
decarboxylase inhibitor (e.g. by administering at the
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same time as L-Dopa/DC inhibitor) to reduce (gastrointestinal) side effects.

Second-line treatment
Drug treatment

Folinic acid Cerebral folate deficiency may occur in
BH4Ds, most prominently in DHPRD. However, there is
risk of development of cerebral folate depletion in the
other BH4Ds too, as long-term administration of L-Dopa
in high doses can result in reduced availability of these
methyl groups due to the methylation of L-Dopa to 3-Omethydopa (3-OMD) [51].
The therapeutic use of folinic acid in BH4Ds is reported in more than 14 AR-GTPCHD cases in 3 studies,
in approximately 40 PTPSD patients in 2 studies, in 262
DHPRD cases in 37 studies, and in 1 SRD patient. There
is no literature available for the use of folinic acid in
PCDD and AD-GTPCHD.
Assessment of the clinical efficacy of folinic acid supplementation is substantially influenced by the use of
various co-medications in the vast majority of patients
or by the lack of data on the clinical course following
the introduction of folinic acid.
The positive effects of folinic acid (in combination
with other medications) included improvement in motor
and cognitive function in movement disorders or epileptic seizures. The rare reports on the change of a patient’s
clinical status after introducing folinic acid claimed improvement in overall condition, in seizure control and
neurologic status, and in the CSF neurotransmitter profile [63, 128, 129]. In the only DHPRD patient treated
solely with folinic acid monotherapy (apart from Phereduced diet), improvement of tremor, drowsiness, hypersalivation, and in the frequency of myoclonic seizures
was noticed [130].
In some patients, the addition of folinic acid did not
change the clinical status or improve the CSF neurotransmitter profile [24, 125].
In 2 patients, adverse effects consisting of vomiting, irritability, and changes in sleep pattern were observed;
however, these patients were treated concurrently with
other medications. Otherwise, there are no reports of
negative effects that could be related to the addition of
folinic acid supplementation to the treatment regimen.
It is important to note that folic acid, a non-naturally
occurring form of folate used to fortify food, is contraindicated in this condition, as it competitively binds to the
folate receptor alpha (FRα), resulting in reduced 5MTHF transport into the brain [61].
R#41 (strong): Folinic acid supplementation should be
used in patients with DHPRD. Note: Cerebral folate deficiency may even be aggravated by the administration of
folic acid!
R#42 (conditional): Folinic acid supplementation
should be considered in any patient with BH4D found to
have low 5-MTHF concentration in CSF.

Dopamine agonists Dopamine agonists (DA) exert their
function by direct postsynaptic activation of dopamine receptors. Ergot-derived DAs that have a strong serotonergic (5HT2b) receptor interaction (cabergoline and
pergolide) are associated with cardiac valvulopathy and
other fibrotic adverse events, and have been removed from
the market in many countries. Ergot-derived DA without
5HT2b agonist action (bromocriptine) have an overall
lower risk. However, pulmonary, retroperitoneal, and
(peri) cardial fibrosis have been described with a doseeffect relationship [131]. Non-ergot DAs (apomorphine,
piribedil, pramipexole, ropinirole and rotigotine) seem to
possess a very low and statistically insignificant risk of fibrotic complications and are preferred in clinical practice
[131]. Potential benefits of DAs are related to their longer
bioavailability in the synaptic cleft leading to equalised LDopa/DC inhibitor stimulation of dopaminergic terminals
in the striatum [132].
The use of DA in BH4Ds as complementary drug
treatment was documented in 12 AD-GTPCH patients, 5
PTPSD and 5 DHPRD patients, and in 8 patients with
SRD. No AR-GTPCHD or PCDD patient receiving DA
has been reported.
The most commonly used DA was pramipexole (16
patients) followed by bromocriptine (10 patients) and
cabergoline (5 patients). Reports on the use of other DA
are very scarce and limited to AD-GTPCHD.
Among BH4D patients, DAs were most commonly
used concomitantly with L-Dopa/DC inhibitor, 5-HTP,
sapropterin dihydrochloride, Phe-reduced diet or folinic
acid treatment, rarely in monotherapy or in combination
with a MAO inhibitor. In the majority of patients, the
use of DAs allowed for a significant reduction of LDopa/DC inhibitor doses, less frequent daily administrations and an improvement of the residual motor symptoms (if specified, mainly parkinsonian symptoms such
as tremor, bradykinesia, hypomimia, dysarthria etc.).
Furthermore, DAs were reported to beneficially affect LDopa/DC inhibitor adverse effects, namely L-Dopa induced dyskinesia and mood swings [133–139].
Reported DA side effects comprise mainly behavioural/psychiatric disorders; impulse control disorders,
including pathological gambling, compulsive buying, and
hypersexuality, were reported almost exclusively under
pramipexole treatment [136]. Symptoms were dosedependent and subsided after adequate treatment adjustment. In a few patients, worsening of motor symptoms
(dystonia, dyskinesias), weight loss or unspecified negative events led to the discontinuation of DA treatment
[32, 137]. No fibrotic complications have been described.
R#43 (conditional): Dopamine agonists can be considered as second line treatment in all BH4Ds (apart
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from PCDD) in combination with first line treatment
options if residual symptoms persist despite L-Dopa/DC
inhibitor treatment or if dose-limiting L-Dopa/DC inhibitor- associated adverse events occur. Non-ergot derived DAs (pramipexole, ropinirole, rotigotine) or ergotderived DA without 5HT2b agonist action (bromocriptine) are preferred.
R#44 (GPP): Cardiac screening before and during
treatment with bromocriptine (ergot derived DA) is indicated because of the potential risk of cardiac fibrosis.
Selective monoamine oxidase (MAO) inhibitors MAO
inhibitors prevent the breakdown of dopamine and serotonin in the synaptic cleft. The effect of selective MAO inhibitors was described in more than 2 AR-GTPCHD cases
in 2 studies, in 4 AD-GTPCHD patients in 4 studies, in
roughly 19 PTPSD patients in 5 studies, in 8 DHPRD
cases in 4 studies, and in more than 7 SRD patients in 7
studies. For PCDD, no evidence is available. All studies describe the effect of selective MAO inhibitors only in combination with L-Dopa/DC inhibitor, dopamine agonists, 5HTP, sapropterin dihydrochloride, selective serotonin reuptake inhibitors (SSRIs), Phe-reduced diet or folinic acid.
Selegiline (n = 36 cases) and rasagiline (n = 1 case) are the
only selective MAO inhibitors used [31]. No studies were
found on tranylcypromine or phenelzine. The majority of
studies described an improvement in at least one clinical
endpoint (e.g. dystonia, fatigability, sleep, motor development or seizure control) or in lowering L-Dopa doses; an
effect on motor fluctuations (on-off phenomena) was described, too. Some studies reported an unclear outcome.
Side effects of MAO inhibitors alone (diarrhoea or constipation, drowsiness or insomnia, dry mouth) were not reported. One patient with SRD developed dyskinesia after
adding SSRI to the treatment regimen [104].
R#45 (conditional): MAO inhibitors can be considered as second line treatment in AR-GTPCHD, ADGTPCHD, PTPSD, DHPRD, and SRD in combination
with first line treatment options although little or no evidence is available.
R#46 (GPP): The members of the guideline group
consider selective MAO inhibitor a treatment option in
case of dose-related symptom fluctuations and druginduced dyskinesia or motor fluctuations. Use should be
guided by availability of the drug and experience of the
treating physician. The members of the guideline group
judged MAO inhibitors to have fewer side effects compared to dopamine agonists.
Third-line treatment
Drug treatment

Anticholinergic drugs Anticholinergic drugs (e.g. trihexyphenidyl) are commonly used to treat movement
disorders, especially dystonia and parkinsonism. The
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current hypothesis is that anticholinergic drugs influence
the relative imbalance between dopaminergic and cholinergic pathways, however, the exact mechanism of action is unclear [140]. The effect of anticholinergic drugs
in BH4Ds was described in 17 patients with ADGTPCHD in 8 studies and in 4 patients with SRD in 3
studies. For AR-GTPCHD, PTPSD, DHPRD, and PCDD,
no published evidence is available.
Trihexyphenidyl (> 15 cases), benztropine (> 2 cases),
and methixene (> 1 case) were the anticholinergic drugs
used [139]. In AD-GTPCHD, most patients first received
L-Dopa/DC inhibitor. Trihexyphenidyl was added due to
incomplete control of symptoms on L-Dopa/DC inhibitor alone and/or due to dyskinesia at higher L-Dopa/DC
inhibitor doses [141, 142]. In the majority of ADGTPCHD patients, a moderate to excellent effect on
dystonia and tremor was noted; however, not all patients
exhibited clinical benefit. For SRD, positive effects of
benztropine supplementation are described in two patients without providing further details. Typical anticholinergic side effects (dry mouth, dry eye, blurred
vision (pupil dilation), constipation, urinary retention,
reduced sweating) were not described in BH4Ds.
R#47 (conditional): Consider anticholinergic agents
as third-line treatment in AD-GTPCHD and, based
on the pathophysiological background, also in ARGTPCHD, SRD, PTPSD, and DHPRD patients in
case of incomplete control of symptoms with LDopa/DC inhibitor. For PCDD, no recommendation
is possible due to lack of evidence.
COMT inhitibors The inhibitors of catechol-O-methyl
transferase (COMT) prevent the action of this enzyme,
which is involved in the breakdown of catecholamines
and, thus, has a direct impact on the pharmacodynamic
and pharmacokinetic properties and the behaviour of
levodopa. By this mechanism, COMT inhibitors have the
potential to increase the availability of catecholamine
neurotransmitters in the CNS, particularly dopamine.
The indication for this add-on treatment would be to reduce motor fluctuations associated with L-Dopa treatment. The only evidence available in the literature for
treatment of BH4Ds is for entacapone.
Treatment with entacapone was described in 4 ADGTPCHD cases in 3 publications, 8 PTPSD cases in 4
studies, in 14 DHPRD patients in 3 studies. For ARGTPCHD, PCD, and SRD, no literature evidence is
available. There are no descriptions of COMT inhibitor
monotherapy in the BH4D cohort. All patients were
treated concurrently with L-Dopa/DC inhibitor, DA, 5HTP, sapropterin dihydrochloride, Phe-reduced diet or
folinic acid.
The assessment of clinical efficacy was yet again problematic due to insufficient data on the clinical course
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after initiating COMT inhibitors. Clear positive effects
could not be obtained for PTPSD and AD-GTPCHD.
Decreased prolactin levels were documented after entacapone introduction in DHPRD. No specific side effects
commonly related to COMT inhibitors (dyskinesia,
hyper−/hypokinesia, gastrointestinal problems with nausea, constipation or diarrhea) were reported among
BH4D patients. General dose recommendations can be
used.
R#48 (conditional): The use of COMT inhibitors can
be considered as third line treatment in all BH4Ds apart
from PCDD. The members of the guideline group consider COMT inhibitors as a treatment option in patients
suffering from motor fluctuations with L-Dopa/DC inhibitor treatment.

Selective serotonin reuptake inhibitors (SSRI) SSRIs
act by decreasing the presynaptic reuptake of serotonin,
which leads to its prolonged bioavailability in the synaptic cleft and better postsynaptic receptor occupancy. The
rationale for their use in BH4Ds is the presence of symptoms attributable to serotonin deficiency such as psychiatric and behavioural disorders and sleep problems.
The use of SSRIs (sertraline, fluoxetine and others)
was reported in 1 patient with AR-GTPCHD, 11 patients
with AD-GTPCHD in 4 studies and in 4 patients with
SRD in 5 studies. For PCD, DHPRD and PTPSD no literature evidence is available.
For all patients with SRD, improvement of disease related symptoms (including improved alertness, sleep
time and dystonia) were documented [96, 104]. In 10
out of 11 patients with AD-GTPCHD, depression improved [126, 143]. One patient with AR-GTPCHD experienced worsening of depression [26], and one patient
with SRD had akathisia and dyskinesia/myoclonus while
treatment concurrently with a MAO inhibitor (selegiline) [104].
R#49 (conditional): There is a conditional recommendation for the use of SSRIs in AD-GTPCHD for psychiatric symptoms.
R#50 (conditional): Based on the current evidence,
no definitive recommendation can be given for the use
of SSRIs in AR-GTPCHD, PTPSD, DHPRD, and SRD.
Guideline group members consider SSRIs in individual
cases as third line treatment with caution of possible
side effects if all first- and second-line treatment options
have, over an adequate amount of time, shown to be insufficient to control symptoms. For PCDD, no recommendation is possible due to lack of evidence.
R#51 (GPP): Caution: According to the guideline
group members, the combination of 5-HTP and SSRI
treatment, specifically in very high doses, can induce
serotonin syndrome!
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Melatonin From a pathophysiological perspective, melatonin supplementation for disorders of sleep induction is
reasonable because melatonin is formed from serotonin
and, therefore, may be decreased in a BH4 deficient
state.
Apart from 2 patients with SRD, who were reported to
have reduced night time dystonia and improved sleep
transition, there is very limited evidence for the use of
melatonin in BH4Ds [21, 104]. In the 2 studies with low
or very low level of evidence, no side effects have been
reported.
R#52 (conditional): There is a pathophysiological rationale to consider a trial of melatonin in all BH4D patients facing sleep induction problems before using
other sleep-inducing medications. Prior to this, an
optimization of 5-HTP supplementation should be
reached (except in AD-GTPCH and PCDD).
Acute drug treatments

Baclofen Baclofen is a CNS depressant and skeletal
muscle relaxant used to treat spasticity. In the literature,
there is only one SRD case published in whom baclofen
was used. However, no clear description of its clinical effect is provided [104]. No recommendation is possible
due to lack of evidence.
R#53 (GPP): The application of baclofen could be
considered in patients with complications due to spasticity. The decision should be based on individual clinical
judgment. See the guideline on diagnosis and management of cerebral palsy in young people [144].
Benzodiazepines Benzodiazepines belong to the
broader generally accepted treatment regimen of dystonia. However, for BH4Ds, there is no satisfying evidence for the use of benzodiazepines. A single patient
with SRD is described who experienced no change in the
duration of oculogyric crisis with benzodiazepine treatment [97]. However, the guideline group members describe beneficial effects on prolonged oculogyric crisis in
some patients (personal communication).
R#54 (GPP): Current evidence for benzodiazepine
treatment in BH4Ds is very scarce but a treatment attempt can be considered in specific settings, e.g. in sustained oculogyric or dystonic crises, always based on
individual clinical judgement.
Anti-epileptics The literature evidence for the use of
anti-epileptic treatment in BH4Ds is primarily available
for DHPRD. The use of various anti-epileptic drugs,
most commonly phenobarbital and phenytoin, and always combined with other medications, was reported in
14 cases from 9 studies [93, 94, 145]. Notably, folinic
acid supplementation was reported to improve epileptic
seizures in DHPRD, too [94, 146, 147]. One patient with
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SRD treated with valproic acid was reported, but no details regarding the clinical course were provided. For the
other BH4Ds, the specific antiepileptic drugs used are
usually not specified.
R#55 (GPP): Epileptic seizures are not a cardinal clinical symptom of BH4Ds and should be distinguished by
reliable diagnostic approaches from oculogyric crisis or
dystonic jerks. If required, any antiepileptic treatment
can be used according to the specific indications for different seizure types.
Other supportive therapies

Botulinum toxin injections Botulinum toxin injections
are commonly used to treat focal dystonia. However,
since there are only 3 patients with AD-GTPCHD reported in whom botulinum toxin injections were used,
there is very limited evidence for its application in
BH4Ds. There are no patients described with botulinum
toxin injections as monotherapy. In one case, botulinum
toxin injections were used before the diagnosis of the
underlying BH4D. 2 other cases were concurrently
treated with L-Dopa/DC inhibitor [142, 148], and with
trihexyphenidyl in 1 case, which did not resolve dystonic
symptoms completely (writer’s cramp, blepharospasm,
and retrocollis). All patients improved with botulinum
toxin injections; however, the co-administration of other
medications does not permit evaluation of the effect of
botulinum toxin alone. Side effects were not reported in
the literature. Dose and application procedure should
follow specific guidelines [149].
R#56 (conditional): Botulinum toxin injections should
be considered as an option in the case of persistent focal
dystonia in AD-GTPCHD if all first- and second-line
treatment options have, over an adequate amount of time,
shown to be insufficient to control these symptoms. For
AR-GTPCHD, DHPRD, PTPSD, SRD, and PCDD, there is
no recommendation possible due to lack of evidence.
Multidisciplinary treatment Although there are not
sufficient studies or reports on the impact of multidisciplinary treatment in BH4Ds available, involvement of a
broad team with specialists in physiotherapy, speech
therapy, occupational therapy, feeding and nutritional
assessment, and (neuro-) psychological treatment should
always be part of the complex care provided to BH4D
patients to improve patient care, prevent secondary
complications, and promote neurological development.
Psychiatric therapy There is very limited evidence for
the use of psychiatric therapy in the cohort of BH4D patients. It is presumed that at least some patients with psychiatric disturbances received psychiatric pharmacothera
py; however, the literature is scarce. There are 2 published
cases of adult patients with AD-GTPCHD who received
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electroconvulsive therapy (ECT) [150, 151]. One of the patients with psychosis [151] developed a neuroleptic malignant syndrome due to haloperidol treatment followed by a
prolonged catatonic state, which required ECT. In the
other patient, a combination of SSRI and 5-HTP did not
prevent the emergence of a delusional depression; he was
therefore treated with ECT. ECT therapy had a positive effect in both cases. Side effects of ECT are only mentioned
in one case: after the third and fourth treatment sessions,
the patient developed postictal disorientation and agitation lasting about 30 min [150]. Overall, no recommendation for a specific psychiatric therapy for the treatment of
psychiatric disorders in BH4Ds is possible due to lack of
evidence.
Experimental therapies

New experimental therapies are listed at https://clinicaltrials.gov.
Drugs to avoid in BH4 disorders

Drugs with antiemetic and antipsychotic properties, acting as central dopamine antagonists, should be avoided
in BH4Ds since they have the potential to worsen symptoms of dopamine deficiency [152]. Metoclopramide
should not be used for the treatment of nausea. Trimethoprim/sulfamethoxazole should be avoided because it is reported to cause parkinsonian symptoms in a
confirmed patient with DHPRD [146]. This patient was
co-treated with L-Dopa/carbidopa and 5-HTP when
treatment with trimethoprim-sulfamethoxazole was initiated (folinic acid was added afterwards). The adverse effects reported in this patient were clearly related to the
initiation of the antibiotic and their disappearance was
related to discontinuation of the treatment [146]. Due to
the inhibitory effect of methotrexate on DHPR and the
interaction with dihydrofolate reductase (DHFR), this
treatment may lead to HPA and early neurotoxicity, possibly combined with folate deficiency [153].
Prenatal treatment

Dopamine signalling is important already for intrauterine (brain) development [154]. Prenatal oral treatment with L-Dopa/carbidopa to the mother of a genetically confirmed AR-GTPCHD foetus was shown to
prevent development of the severe phenotype related to
biallelic GCH1 mutations [68].
R#57 (research): Prenatal treatment with levodopa
can be beneficial. Since the experience of prenatal treatment in BH4Ds is based on single case studies with low
to very low evidence, it would be desirable to develop a
protocol for further treatment attempts in a controlled
and standardized trial.
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Follow-up, transition and special situations
Follow-up visits

There are no reports available on standardized follow-up
visits in the BH4D patient cohort. Therefore, recommendations can only be based on clinical experiences or
good clinical practice. Comparable to other inborn errors of metabolism [5, 155], for all BH4Ds apart from
PCDD life-long, systematic follow-up is recommended
to achieve optimal development, to prevent or avoid
treatment side-effects, and to evaluate quality of life. In
addition, it is not known if and when long-term complications occur. Regular standardized follow-ups allow
early identification of patients presenting with such disease related or treatment-related complications.
R#58 (GPP): BH4D patients should be seen at least
yearly by a (child) neurologist with experience in movement disorders or neurometabolic disease, ideally in a
multidisciplinary setting. Infants and young children
who require frequent dose adjustments during the
course of initial dose titration and due to weight gain
need to be seen more frequently (e.g. infants every 3
months; older children at least every 6 months)!
The follow-up visits should include the evaluation of:
– Phe-reduced diet (if applicable): Daily amount of
Phe, intake of amino acid mixture, amino acids in
plasma, full blood count, ferritin, parathormone,
calcium, phosphate, alkaline phosphatase, vitamin
B12
– Current medication: Regular intake? Symptoms of
over−/underdose?
– Neurological symptoms: Motor milestones,
seizures, oculogyric crises, vegetative symptoms
(sweating, fever, nausea, vomiting, stool frequency,
micturition frequency, sleep, behaviour), eating
habits, speech development
– General medical history: Anthropometric data?
Infections? Vaccinations? Narcotics or alcohol
abuse?
– Integration and inclusion measures (if applicable)
– Kindergarten, school, education, occupation
– ECG and/or echocardiography (if under treatment
with dopamine agonists).
– Neuropsychological development
Although there are no studies or reports on the need
for repeated measurement of CSF metabolites as part
of ongoing treatment monitoring, CSF analysis of
HVA, 5-HIAA, and 5-MTHF can be helpful for drug
dose titration or for clarification of otherwise unexplainable clinical irregularities. This is especially true
for younger children in whom the spectrum of
(neurological) symptoms can be broader or more difficult to assess.
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R#59 (GPP): Consider CSF analysis of HVA, 5-HIAA,
and 5-MTHF for drug dose titration or for clarification
of otherwise unexplainable clinical irregularities in all
BH4Ds apart from PCDD. For the lumbar puncture
standard oral treatment should be interrupted as short
as possible.
Transition

As in many other inborn errors of metabolism, there is a
paucity of literature regarding transition from childhood
to adulthood in the BH4Ds. However, a successful transition to adult care requires the coordinated cooperation
of many disciplines. A transitional consultation with the
participation of paediatric and adult neurological institutions is very valuable [156]. During the transition
process, the following aspects should be considered
among others: Role changes of patients, parents and
caregivers, active involvement of stakeholders in the
planning and decision-making processes, comprehensive
knowledge about the illness and its course.
R#60 (GPP): Begin planning early for transition of
BH4D patients to adult care in specialized centers.
Multidisciplinary care should be continued.
Anaesthesia

Reports on anaesthesia in BH4D patients are very scarce
in the literature, and do not indicate any particular risks.
From the metabolic perspective BH4D patients do not
require any special precautions and anaesthesia can follow standardized procedures. No specific anaesthetic
drugs need to be avoided.
R#61 (GPP): Anaesthesia in BH4D patients may follow
standard protocols. After the operative procedure standard oral treatment should continue as soon as possible.
Genetic counselling

On the grounds that BH4Ds are inherited metabolic disorders, it is good clinical practice to offer genetic counselling to parents and/or patients. In addition, molecular
genetic analysis is the preferred prenatal testing method
for all BH4Ds (see R#29).
R#62 (strong): All patients or parents of patients with
BH4Ds should be offered standard genetic counselling if
available in local care settings.
Pregnancy

There are few cases in the literature reporting obstetric
and paediatric outcomes in pregnancies of patients with
BH4Ds [157]. It is important to control disease-related
symptoms, adjust the treatment if needed, and monitor
the development of the foetus. Therefore, close supervision by a multidisciplinary team (dietitian, (neuro) metabolic consultant, neurologist, gynaecologist, geneticist) is
essential during the course of pregnancy and afterwards.
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R#63 (strong): Intensive supervision during and after
the pregnancy by a multidisciplinary team should be
provided.
Patient advocacy groups

Currently, there are the following non-profit volunteer
organizations, representing children and families who
are affected by a paediatric neurotransmitter disease including BH4Ds:
– Pediatric Neurotransmitter Disease Association
(www.pndassoc.org) - USA
– Spanish neurotransmitter diseases association “De
neu” (www.deneu.org) - Spain
– German group for patients and parents with all
kinds of neurotransmitter related disorders (www.
dig-pku.de/wcf/index.
php?neurotransmitterstoerungen-nts/) - Germany
– Organization to support families with children
suffering from neurotransmitter diseases (www.
hrabrisa.rs/en/) - Serbia
Regular updates on patient advocacy groups can be
found under https://intd-online.org/patients/.

Conclusion
This is the first consensus guideline for the diagnosis
and management of BH4 deficiencies. All recommendations are based on the available literature evidence and
were phrased in a transparent consensus process by the
iNTD guideline working group. The guideline is
intended for clinicians, metabolic biochemists and paramedical specialists involved in the care of patients with
BH4 deficiencies. It will help to harmonize clinical practice and to standardize and improve care for BH4 deficient patients.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13023-020-01379-8.
Additional file 1: Table S1. Key questions for the Guideline on
diagnosis and treatment of BH4 deficiencies.
Additional file 2: Figure S2. Flow chart showing the systematic
literature search, and number and type of included sources.
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DBS: Dry blood spot; DC: Decarboxylase; DCI: Decarboxylase inhibitor;
DHFR: Dihydrofolate reductase; DHPG: 3,5-dihydroxyphenylglycine; DHPR: qdihydropteridine reductase; DHPRD: Dihydropteridine reductase deficiency;
DOPAC: 3,4-Dihydroxyphenylacetic acid; DRD: Dopa-responsive dystonia;
DT: Dopamine transporter; ECT: Electroconvulsive therapy;
EEG: Electroencephalography; GRADE: Grading of Recommendations,
Assessment, Development and Evaluation; GTPCH: Guanosine triphosphate
cyclohydrolase I; GTPCHD: Guanosine triphosphate cyclohydrolase I
deficiency; GPP: Good Practice Point; HPA: Hyperphenylalaninemia;
HVA: Homovanillic acid; iNTD: International Working Group on
Neurotransmitter Related Disorders; L-Dopa: l-3,4-dihydroxyphenylalanine;
MAO(−I): Monoamine oxidase (inhibitor); MHPG: 3-Methoxy-4hydroxyphenylglycol; MLPA: Multiple ligation-dependent probe amplification;
MS: Mass spectrometry; NBS: Newborn screening; NGS: Next-generation
sequencing; Neo: Neopterin; NOS: Nitric oxide synthase; MODY: Maturity
Onset Diabetes of the Young; PAH: Phenylalanine hydroxylase; PCD: Pterin-4alpha-carbinolamine dehydratase; PCDD: Pterin-4-alpha-carbinolamine
dehydratase deficiency; Phe: Phenylalanine; PKU: Phenylketonuria;
Prim: Primapterin; PTPSD: 6-pyruvoyltetrahydropterin synthase deficiency;
SAM: s-adenosyl-methionine; SIGN: Scottish Intercollegiate Guideline
Network; SR: Sepiapterin reductase; SRD: Sepiapterin reductase deficiency;
SSRI: Selective serotonin reuptake inhibitors; TH: Tyrosine hydroxylase;
TPH: Tryptophan hydroxylase; Tyr: Tyrosine; VLA: Vanillactic acid;
VMA: Vanillylmandelic acid
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